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Abstract 
Autosomal dominant polycystic kidney disease (ADPKD) is a life-threatening genetic 
disorder characterized by the presence of fluid-filled cysts primarily in the kidneys. Mutations in 
either the PKD1 or PKD2 genes are the underlying cause of ADPKD. It is a systemic disorder 
and some of the extra-renal manifestations include polycystic liver, cerebral aneurysms, cardiac 
valve abnormalities and hypertension. Progressive cyst formation and renal enlargement lead to 
renal insufficiency in these patients which need to be managed by life-long dialysis or renal 
transplantation. Epithelial cell proliferation and fluid secretion are two hallmark features of PKD.  
Cux1 is a homeobox gene involved in cell cycle regulation during kidney development. 
In the developing mouse kidney, Cux1 is highly expressed in the nephrogenic zone where 
developing nephrons are present. Cux1 regulates the cell cycle by transcriptional repression of 
the cyclin dependent kinase inhibitors, p21 and p27, thereby increasing cell proliferation. As 
kidney development ceases, Cux1 is downregulated and adult kidneys show only low levels of 
Cux1. Cux1 is ectopically expressed in several mouse models of PKD, as well as, in ADPKD 
patients. Cux1 transgenic mice which overexpress Cux1 develops multiorgan hyperplasia 
including kidney hyperplasia, but they do not develop PKD. This suggests that the 
overexpression of Cux1 and the resultant increase in cell proliferation is not sufficient to cause 
PKD.  
In this particular study, we addressed the hypothesis that Cux1 is required for 
cystogenesis and/or cyst progression in ADPKD. Results from our mouse model which carries a 
collecting duct specific deletion in the Pkd1 gene (Pkd1CD) and a homozygous deletion in the 
Cux1 gene shows that the complete loss of Cux1 results in slowing the cyst initiation process. 
Moreover, a reduction in the gene dosage of Cux1 in Pkd1CD mice led to a slow progression of 
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PKD resulting in the amelioration of the disease. The complete loss of the Cux1 gene and a 
reduction in its gene dosage mediated its effects by the de-repression of the p27 gene resulting in 
reduced cell proliferation. These studies point towards the importance of cell proliferation in the 
pathogenesis of PKD and show that Cux1 is required for cyst progression in ADPKD. 
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Chapter One: Introduction 
Polycystic Kidney Disease (PKD) 
“Every one of us was once a cyst- a blastocyst”. Jared J. Grantham (1) 
Polycystic kidney diseases are characterized by the presence of fluid-filled renal cysts 
and cysts in other epithelial organs (2). PKD patients show progressive cyst formation and 
massive renal enlargement that often leads to end-stage renal disease (ESRD) (3). Normal adult 
human kidneys make up about 0.5 per cent of a person’s total body weight. A PKD patient who 
underwent bilateral nephrectomy after reaching ESRD had a total kidney weight of 22kg, which 
was around 21.6 per cent of his body weight (4). Normal renal tubules, which are approximately 
40µm in diameter, enlarge to form cysts that measure centimeters in diameter (5). Cysts as large 
as 5cm were reported in PKD patients at their ESRD stage (6). PKD is inherited as an autosomal 
recessive (ARPKD) or an autosomal dominant (ADPKD) trait (2, 7).  
ARPKD 
ARPKD has an incidence rate of 1 in 20,000 live births (8, 9) and affects primarily 
neonates and children (2). ARPKD fetuses present with severe polycystic kidneys, biliary tract 
defects and oligohydramnios. Approximately half of the ARPKD neonates die shortly after birth 
due to respiratory insufficiency caused by pulmonary hypoplasia. In surviving patients, 
morbidity and mortality are mainly caused by systemic hypertension, renal dysfunction and 
portal hypertension that result from portal-tract hyperplasia and fibrosis (10). Cysts in these 
patients develop in utero and transient proximal tubular cysts are seen during early fetal 
development. However, the major manifestaion is seen as fusiform dilatation of the collecting 
ducts (2). In ARPKD, cysts are attached and do not separate from the parental tubules (11).  
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Mutations in a single gene, PKHD1, which encodes a trasmembrane protein known as 
fibrocystin/polyductin, causes ARPKD. Fibrocystin is present in cortical and medullary 
collecting ducts and biliary ducts. Subcellular localization of fibrocystin includes basolateral 
plasma membrane, primary cilia and the centrosome in renal epithelial cells (10, 11). Fibrocystin 
is thought to mediate terminal differentiation of the renal collecting ducts and intrahepatic biliary 
ducts (10). 
ADPKD 
ADPKD is one of the most common hereditary disorders in humans. It has an incidence 
rate of 1 in 500 to 1 in 1000 individuals and occurs both in children as well as in adults (2). 
ADPKD occurs more frequently compared to other prominent genetic disorders. It is 10 times 
more common than sickle cell anemia, 15 times more common than cystic fibrosis, and 20 times 
more common than Huntington’s disease. It is a systemic disorder which can have an adult as 
well as in utero onset (12). Extrarenal manifestations in ADPKD include cysts in other epithelial 
organs such as liver and pancreas. ADPKD patients also show connective tissue defects such as 
intracranial aneurysms, cardiac valve abnormalities, aortic dissection and abdominal wall hernias 
(13, 14). Hypertension is a very common symptom in ADPKD patients which often precedes the 
biochemical and clinical manifestations of the disease (15). Progressive loss of renal function is 
seen in ADPKD patients (7, 11).  Renal enlargement in these patients leads to the displacement 
of other organs and with considerable renal enlargement, ADPKD patients look chronically 
pregnant. These patients account for approximately 10% of ESRD cases (7, 11). ADPKD is also 
the third leading cause of ESRD requiring dialysis and transplantation in the United States. 
Medicare costs for treating ESRD in ADPKD patients were found to exceed $200 million per 
year according to a report in 1993 (12).  
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ADPKD genes 
ADPKD is genetically heterozygous. Mutations in the PKD1 gene located on 
chromosome 16p13.3, causes ADPKD in 85% patients. The remaining 15% patients with 
ADPKD have mutations in the PKD2 gene which is located on chromosome 4q21-23 (2, 16). It 
is uncertain if there is a third gene associated with ADPKD as some patients do not show linkage 
to either the PKD1 or PKD2 genes (16, 17). Identical renal and extrarenal manifestations are 
seen in patients with PKD1 or PKD2 mutations. Nevertheless, PKD2 patients show a later onset, 
have longer renal survival and present fewer complications compared to PKD1 patients (2).  
The PKD1 gene is a very large gene and has 46 exons within the 52 kb genomic DNA. A 
region in the PKD1 gene which spans from exon 1 to 33 is duplicated at six other sites on the 
same chromosome. Mutation analysis of the PKD1 gene has been difficult owing to these 
duplicated regions (2). The PKD1 gene has some unusual structural features such as a high GC 
content and multiple simple repeats. Of interest, a 2.5kb polypyrimidine tract is seen in intron 21, 
which may interfere with its replication, transcription and RNA processing (11). The PKD2 gene 
is comparatively smaller than the PKD1 gene and is 25% homologous to a region of the PKD1 
gene (2). Screening of the ADPKD population has discovered 864 PKD1 and 139 PKD2 germ-
line mutations to date (pkdb.mayo.edu). Most of these mutations produce truncated protein 
products due to nonsense changes, splicing defects, frame-shift deletion or frame-shift insertions. 
However, some missense and in-frame mutations have also been described (17). Protein products 
of the PKD1 and PKD2 genes are collectively called polycystins. A detailed account of 
polycystins is given in a later section. 
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ADPKD- a developmental disorder 
The onset of symptoms in ADPKD does not become apparent until the fourth or fifth 
decade of life in an ADPKD patient. However, numerous evidence suggests that cystogenesis 
occurs as early as in utero in these patients. Even with an ultrasound detection threshold of 
>7.0mm, cysts have been detected at birth in ADPKD patients (18). Cysts have also been 
detected in stillborn fetuses, live born babies immediately after birth and in infants (19). A study 
measuring the growth rates of individual cysts in adult ADPKD patients over a period of 3 years 
suggests that cysts that are detected in newborn patients must have grown at exuberant rates in 
utero and at slower rates thereafter (18).  
Mammalian kidney development  
The nephron, which is the functional unit of the excretory system in vertebrates, has 
similar characteristic features in lower vertebrates and also in higher vertebrates such as 
mammals (20). As it develops, the mammalian kidney goes through three spatially and 
temporally different stages known as the pronephros, the mesonephros and the metanephros (20-
23). The mammalian kidney originates from the intermediate mesoderm (IM) which lies in 
between the axial and the lateral plate mesoderm (24, 25). The different stages of mammalian 
kidney development in a mouse embryo are shown in figure 1-1.  
As the first step in mammalian kidney development, the primary nephric duct, also 
known as the Wolffian duct or the pronephric duct, arises from the IM and grows in the rostro-
caudal direction (24, 26). The elongating pronephric duct induces the formation of two sets of 
tubules in the adjacent undifferentiated mesoderm. In the mouse embryo, these inductive events 
take place at embryonic day 8 (E8) and E10 to produce the pronephros and the mesonephros, 
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respectively. The pronephric tubules are rudimentary structures and do not have any functional 
role in the mouse embryo. However, the caudal mesonephric tubules are well developed with 
glomeruli and convoluted proximal tubule-like structures and serve as transient filtration units 
which empty into the nephric duct (24-26). Mesonephros also gives rise to the ductal system of 
male reproductive system in mammals. In humans, the pronephros can be seen by E22 and the 
mesonephros by E24 (22). The mesonephros degenerates as the definitive metanephric kidneys 
form in mammals (24).  
 
 
 
 
 
 
 
Figure 1-1: Stages of kidney development in the mouse embryo. A:  Schematic cross 
section of a mouse embryo at E8.5. Kidneys arise from the intermediate mesoderm (IM, pink) 
which lie between the lateral plate (blue) and the paraxial mesoderm (PM, yellow). B-E: 
Schematic diagrams of different developing kidney structures in the anteroposterior (AP) axis 
in a mouse embryo. B: The pronephric duct arises from the intermediate mesoderm in the 
mouse embryo at E9.0. C: The nephric duct grows caudally until it reaches the cloaca. 
Mesonephric tubules can be seen at E10.0. The mesonephric tubules which are found more 
caudally, are more developed compared to the proximal ones. Posterior cells of the 
intermediate mesoderm specialize to form an aggregate called metanephric mesenchyme 
(MM, green).  MM gives rise to all the segments of the nephron. D: Ureteric bud (UB), an 
outgrowth from the nephric duct invades the MM by E10.5. UB gives rise to the collecting 
system of the kidneys. E: The UB bifurcates and the induced mesenchyme, known as the cap 
mesenchyme surrounds the tips of the UB. Reproduced with permission from Dressler, 2009 
(25).  
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The functional kidney in adult mammals- the metanephros, forms at the posterior end of 
the IM (25). An outgrowth of the primary nephric duct called ureteric bud (UB) extends into the 
surrounding specialized region of the IM known as the metanephric mesenchyme (MM). The 
MM contains the progenitor cells of nephrons, the functional units of the adult kidney. The MM 
also provides inductive signals for the primary nephric duct to invade and form the UB at its 
caudal end. Thus, the epithelial cells of the UB invade the MM and undergo branching 
morphogenesis to generate the collecting system of the kidneys. At the same time, mesenchymal 
cells from the MM aggregate around the tips of the newly formed UB branches and begin a 
mesenchyme-to-epithelial conversion (MET). This process is called nephrogenesis as it 
generates the nephron epithelia (24, 27). During nephrogenesis, the mesenchymal aggregates that 
form around the UB go through three different stages known as the polarized renal vesicle, the 
comma-shaped body and the S-shaped body. One end of the renal vesicle remains in contact with 
the UB epithelium and two clefts are formed in the renal vesicle, one after the other, to form the 
comma and the S-shaped bodies, respectively. The distal end of the S-shaped body that remained 
in contact with the UB fuses with it to form a single, continuous epithelial tubule. Subsequently, 
endothelial cells invade the more proximal cleft in the S-shaped body and form the glomerular 
tuft. The ureteric bud branches continuously, inducing new nephrons along the radial axis of the 
kidney. By virtue of this process, the oldest nephrons are found close to the medullary region 
whereas the youngest nephrons are located more peripherally in the nephrogenic zone in a 
developing kidney (24). In the mouse embryo, metanephric induction starts at E10.5 and 
nephrogenesis continues until a week after birth (25, 28). In humans, the metanephros begins 
development at around E35 to E37 and nephrogenesis ceases at approximately 34 weeks of 
gestation (22, 18). The different stages in nephrogenesis are shown in figure 1-2. 
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Figure 1-2: Stages of nephrogenesis The adult metanephric kidney in mammals develops by 
a reciprocal interaction between the epithelial UB and the MM. During the condensation stage, 
the loose mesenchymal cells of the MM condense around the tips of the epithelial UB. The 
mesenchymal cells undergo mesenchyme-to-epithelial conversion (MET). After the 
condensation stage, the induced mesenchyme forms the comma and S-shaped structures. Later, 
the tubules elongate and the podocytes in the golmeruli fold to give rise to a mature nephron. 
Reproduced with permission from Brenner and Rector’s, The Kidney (130). This figure was 
originally published in reference 132.  
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Polycystins, their expression pattern and functions 
Polycystin-1 (PC1), protein product of the PKD1 gene, is an integral membrane protein 
with a large extracellular N-terminal domain (~3000 amino acids), eleven transmembrane 
domains (~1000 amino acids) and a small C-terminal cytosolic domain of about 200-225 amino 
acids (2, 29). The extracellular domain of PC1 contains a region which is homologous to the sea 
urchin protein, receptor for egg jelly or REJ. Regulation of ion transport in the sea urchin sperm 
involves the REJ module of the REJ protein. Likewise, the REJ domain in PC1 is also thought to 
be involved in ion transport (30). The PC1 extracellular domain also contains several other 
domains such as leucine-rich repeats (LRRs), a C-type lectin domain, LDL-A region and 
multiple Ig-like domains or PKD domains, all of which are implicated in cell-cell or cell-matrix 
interactions (2, 11, 14, 31). The first cytoplasmic loop of PC1 contains a lipoxygenase domain 
(PLAT domain named after Polycystin-1, lipoxygenase and alpha toxin) which is essentially a β-
sandwich domain. PLAT domains are usually involved in protein-protein or protein-lipid 
interactions, and in PC1, the presence of PLAT domain may indicate its interaction with other 
proteins (32).  
The cytoplasmic tail of PC1 is found to bind heterotrimeric G proteins in vitro, activate 
the AP-1 transcription factor and take part in the regulation of Wnt signaling (33). The 
cytoplasmic tail contains a coiled-coil domain with which it interacts with polycystin-2 (PC2), 
the protein product of the PKD2 gene (11). A sequence motif that is rich in proline, glutamic 
acid, serine and threonine (PEST), which facilitates ubiquitin-mediated degradation, is also seen 
in the C-tail of PC-1 (34). The PC1 C-tail also contains a putative nuclear localization sequence 
(NLS) that consists of two stretches of basic amino acid residues (35).   
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PC1 is widely expressed in organs such as kidney, liver, brain, pancreas, small intestine, 
lungs and heart (40). PC1 is present on the plasma membrane at focal adhesions, desmosomes, 
tight junctions and adherens junctions and also in the shaft and basal body of primary cilia (2, 16, 
36). PC1 is also expressed in urinary exosomes, which are small vesicles (50-100nm) secreted by 
the renal epithelial cells into the urine. Normal urine shows the presence of thousands of proteins 
Figure 1-3: Structure of polycystins. Polycystin-1 has a large extracellular domain, 11 
transmembrane domains and a short cytoplasmic C-terminal tail. The coiled coil domain in 
the C-terminal end of PC1 interacts with the C-terminal tail of Polycystin-2. Polycystin-2 
has cytoplasmic N and C-terminus. Together, PC1 and PC2 mediate calcium entry into cells. 
Redrawn from references 2 and 11. 
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and most of these proteins are packaged into exosomes and shed into the urine. Exosomes are 
products of the multivesicular body sorting pathway (MVB). The MVB-sorting pathway consists 
of the endocytosis of the integral membrane proteins to form endosomes, fusion of these 
endosomes with the MVB and finally fusion of the MVB with the apical plasma membrane to 
release exosomes (37, 38).  
PC2, the protein encoded by the PKD2 gene, is also a membrane associated protein with 
six transmembrane domains and cytoplasmic N- and C- terminal domains. PC2, also known as 
TRPP2, is a member of the family of transient receptor potential (TRP) ion channels. It is a non-
selective cation channel permeable to Ca2+, Na+ and K+ ions. The channel activity of PC2 is 
modulated by a rise in the intracellular calcium levels. PC2 is insensitive to two other ligand-
gated calcium channels, IP3 receptors and ryanodine recptors and hence is proposed to be a third 
class of calcium release channels in addition to the other two. PC2 is shown to form heteromeric 
channels with two other TRP family members, TRPC1 and TRPV4 (36).  
PC2 is found on the apical and basolateral plasma membrane, endoplasmic reticulum, 
Golgi, shaft and basal bodies of the  primary cilia, and also in urinary exosomes (11, 16, 36). The 
trafficking of PC2 among the ER, Golgi and plasma membrane is modulated by the 
phosphorylation of an acidic cluster present on its C-terminal tail by casein kianse II (36). Most 
of the cellular pool of PC2 is found in the intracellular compartments where it modulates the 
release of calcium from intracellular stores. There are at least two cytoplasmic domains in PC2, 
one in the N-terminus and the other in the C-terminus that contribute to the oligomerization of 
PC2. The C-terminus of PC2 contains a coiled-coil domain with which it interacts with PC1, an 
EF hand characteristic of calcium binding proteins and an ER retention signal that localizes PC2 
to the ER and Golgi compartments (34). 
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Expression of polycystins during kidney development and in ADPKD 
The expression pattern of polycystins in the developing human fetal kidneys between the 
gestational ages of 13- 40 weeks has been described (31, 39). PC1 and PC2 are weakly expressed 
in early nephrogenic precursors such as comma and S-shaped bodies. Weak but detectable 
expression of the polycystins was also seen in the proximal and distal branches of the ureteric 
bud. Maturing proximal and distal tubules and collecting ducts showed a marked level of 
expression of the polycystins. While proximal tubules sustained polycystin expression only until 
28 weeks of gestation, both cortical and medullary collecting ducts maintained the expression 
pattern until 40 weeks of gestation. Analysis of adult human kidneys also showed a weak 
expression pattern of polycystins in the proximal tubules. Continued expression and 
colocalization of PC1 and PC2 were seen in the medullary collecting ducts (39). 
The expression pattern of murine PC1 was analyzed by Geng et al. Similar to the 
expression profile of PC1 in humans, murine PC1 was widely expressed in the kidneys. It was 
also expressed in other organs such as brain, liver, pancreas, small intestine, lungs and heart. 
Developing kidneys showed the weakest expression of PC1 in the ureteric bud tips which 
suggest that PC1 may not be required for nephrogenic induction. Ureteric bud derivatives such as 
collecting ducts, papillary ducts and renal pelvis show a strong expression of PC1 during later 
developmental stages. This tubular expression of PC1 continued after birth and was maintained 
until the third week postnatally after which PC1 expression becomes undetectable (40). 
Murine embryonic ectoderm and endoderm shows the presence of PC2 by E6.0. PC2 is 
widely expressed in the embryonic stages, while its expression becomes more restricted after 
birth. By E12.5, metanephric ureteric bud showed low-intensity staining for PC2. Proximal 
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tubules showed a weaker staining, while distal tubules strongly express PC2 by E15.5. Medullary 
collecting ducts showed the expression of PC2 by postnatal day 14 (41).   
Ward et al described the expression pattern of PC1 in adult human tissues, in ADPKD 
kidneys and also in polycystic liver (31). Quantification of PC1 expression in adult human 
tissues showed highest expression in brain, lowest in thymus and an intermediate level of 
expression in the kidneys. This widespread expression of PC1 in a variety of tissues may explain 
the systemic nature of ADPKD. End-stage ADPKD kidneys and an ADPKD polycystic liver 
analyzed, showed an approximately 2-fold increase in the Polycystin-1 mRNA expression level 
compared to the normal kidneys and livers respectively (31). 
Polycystins as mechanosensors 
ADPKD, together with many other diseases that present with renal cysts, was inducted 
into a family of diseases known as ciliopathies. This came after the discovery that many 
cystoproteins that cause renal cysts localize to the once disregarded organelle, the non-motile 
primary cilia. Primary cilia are sensory organelles which protrude from the center of epithelial 
cells. They grow out from the basal bodies or centrosomes and are microtubule-based structures. 
Primary cilia are highly conserved in evolution and are used to detect a wide variety of physical 
and chemical stimuli that are of mechanical, photonic, olfactory or hormonal in nature (42). 
The association between cilia and PKD was first discovered when mutations in Tg737, 
responsible for renal cystic disease in the orpk mouse model of PKD, showed stunted primary 
cilia in their renal epithelial cells. The orthologue of Tg737 in Chlamydomonas, Ift88, is required 
for intraflagellar transport and assembly of motile cilia. Subsequently it was shown that 
polycystins and fibrocystins also localize to the primary cilia (42). 
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 Renal tubular epithelial cells, including all the segments of the nephron and the 
collecting ducts, show the presence of a single primary apical cilium (13). Fluid flow in renal 
tubular epithelial cells bends the primary cilium on their surface. PC1 present on the cilium is 
thought to sense the fluid flow with its large extracellular domains, in turn activating the 
associated PC2 calcium channels. This allows calcium influx which leads to a calcium induced 
calcium release from other intracellular Ca2+ stores leading to various genetic changes in cells 
(16, 43). A model for polycystins signaling through primary cilia is shown in figure 1-4 B. 
A flow-Ca2+ imaging system was used to test the functionality of PC1 on primary cilia. 
Mouse embryonic kidney cells responded to fluid flow at a rate comparable to the physiological 
urine flow rate. However, Pkd1 null cells failed to respond to fluid flow rates higher or lower 
than those detected by wild type cells confirming that PC1 is required to detect fluid flow. 
Atomic force microscopy studies revealed that the PKD domains on PC1 exhibit remarkable 
mechanical strength, further supporting the mechanosensory function of PC1 (36).  
Other diseases such as nephronophthisis (NPHP), Bardet-Biedl syndrome (BBS) and 
Orofaciodigital syndrome also present with renal cysts, and the protein products of the genes 
mutated in these diseases all localize to the cilia, basal bodies or centrosomes. In fact, protein 
products of all the genes that cause renal cystic diseases in humans, mice and zebrafish localize 
to the primary cilia, basal bodies or centrosomes placing primary cilia at the center of cystic 
kidney diseases. However, since the cystoproteins also localize to many other sub-cellular 
locations, a ciliary defect alone cannot be attributed as a primary defect in these diseases. 
Nevertheless, a systemic nature of different types of PKDs, BBS and NPHP favors the ciliary 
hypothesis because of the presence of cilia in many of the organs affected in these diseases (42).  
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Channel activity of polycystins 
The last six transmembrane domains of PC1 share significant sequence homology with 
the domains of Na+ and Ca2+ channels and transient receptor potential (TRP) channels. However, 
by itself PC1 cannot form ion channels since PC1 overexpression alone does not yield any 
measurable channel activity (36). 
In response to local increases in intracellular calcium, PC2 releases calcium from 
intracellular stores. The loop between the fifth and the sixth transmembrane domains is involved 
in the calcium conducting activity of PC2. The third transmembrane domain is also involved 
partially in this process. In addition to its direct involvement in calcium induced calcium release, 
PC2 also indirectly regulates calcium levels in the cell by interacting with two intracellular 
calcium channels, ryanodine receptors and IP3 (inositol 1,4, 5-triphosphate receptor) receptors. 
PC2 inhibits ryanodine receptor mediated calcium release by binding to the channel in its open 
state thereby decreasing its conductance. Direct binding between the C terminus of PC2 and 
IP3R modifies IP-3 induced calcium flux (34).  
An interaction between PC1 and PC2 generates a functional ion channel. It is not certain 
whether this is through the activation of PC2’s intrinsic channel properties, or due to the 
formation of a functional complex between these two proteins (34). Owing to the calcium 
channel activity of polycystins, genetic mutations in any of the polycystins disrupt intracellular 
calcium regulation leading to abnormal cell proliferation. A study measuring the steady-state 
intracellular calcium levels in normal and ADPKD renal cell cultures found that calcium levels 
in ADPKD cells are 20nM lower than in normal renal cells (44).  
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Other functions of polycystins 
PC1 found on the plasma membrane may interact with PC2 present on the adjacent 
endoplasmic reticulum (16). PC1 may also act as a receptor for a ligand which is yet to be 
identified. Upon receiving a stimulus, PC1 may signal to the interior of the cell by its interaction 
with PC2 on the plasma membrane. This signaling event can result in the activation of calcium 
channels, an increase in cytoplasmic calcium which leads to exocytosis and changes in gene 
expression (Figure 1-4 A) (2).  
Cellular signaling pathways modulated by the polycystins can be broadly classified into 
three categories: G- protein activation, growth regulation and Wnt pathway modulation (34). 
G-protein activation 
PC1 functions as a G-protein coupled receptor (GPCR) which can regulate cell 
proliferation, fluid secretion, cell polarity and differentiation (Figure 1-3 C and D) (2). PC1 
contains sequences that are found in GPCRs. These include a proteolytic site domain and a 
polybasic domain found in its C-terminal tail, which has been shown to activate Gi/G0 proteins 
in vitro. However, PC1 is an atypical GPCR since it has 11 transmembrane domains in contrast 
to 7 transmembrane domains found in typical GPCRs. PC1 has been shown to bind and stabilize 
the regulator of G-protein signaling 7 (RGS7), member of a family of proteins which are capable 
of accelerating the hydrolysis of GTP bound to the Gα subunit of G-proteins. Moreover, RGS7 
was shown as a candidate modifier gene in a mouse model of PKD (29). 
Downstream signaling through GPCRs can lead to the activation of c-Jun N-terminal 
kinase (JNK) and activator protein-1 (AP-1) pathways. The JNK/AP-1 pathway controls various 
cellular processes such as cell cycle regulation, cell growth, differentiation, apoptosis and 
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inflammation. In Drosophila, JNK signaling is involved in the developmental regulation of 
planar polarity, epidermal adhesion and integrity (29). Many of these pathways controlled by 
JNK/AP-1 are also involved in the pathogenesis of PKD. 
Arnould et al demonstrated the activation of the JNK/AP-1 pathway via the PC1 C-
terminal tail. Several components of this pathway such as protein kinase C α (PKC α) and small 
G proteins such as Cdc42 and Rac1 were involved in mediating this signal (45). Parnell et al 
showed that the activation of JNK/AP-1 pathway is mediated by signaling through Gα and Gβγ 
subunits (29). Moreover, activity of the AP-1 components such as ATF-2, c-jun and c-fos were 
increased in ADPKD patients and in a hypomorphic Pkd1 mouse model further suggesting the 
involvement of JNK/AP-1 pathway in PKD pathogenesis (46). 
Additional evidence for PC1 signaling through G-proteins comes from the observation 
that PC1 activates phospholipase C (PLC), an event mediated by the Gαq. This leads to the 
subsequent activation of the calcineurin/ NFAT (nuclear factor of activated T-cells) pathway. 
Signaling through this pathway also relates to the function of polycystins as regulators of 
intracellular calcium levels. Exogenous expression of the PC1 C-tail results in an increase in 
calcium levels in a reaction requiring PLC β. This intracellular increase in calcium leads to the 
activation of calcineurin, a serine-threonine phosphatase which dephosphorylates NFAT. 
Activated NFAT translocates to the nucleus and regulates target genes at composite NFAT/AP-1 
elements. In addition to the evidence for PC1 mediating NFAT activation, NFAT was also 
shown to be expressed in renal tubular epithelial cells of developing and adult mice which also 
correlated with the temporal expression of PC1 in these cells.  This suggests that NFAT and PC1 
may work together in a pathway (47). 
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Growth regulation 
In accordance with the increased cell proliferation defects seen in PKD, PC1 and PC2 are 
directly involved in regulating the cell cycle. One of these mechanisms includes signaling 
through the JAK-STAT pathway (Figure 1-4 E-F). Signaling through this pathway leads to the 
activation of STAT1 and STAT3, subsequent upregulation of a cyclin dependent kinase inhibitor 
(CKI) p21 and the inhibition of cyclin dependent kinase 2 (cdk2) which ultimately leads to cell 
cycle arrest at the G0/G1 transition (Figure 1-4 G) (2, 48).  
Another evidence for a direct role of polycystins in the cell cycle was shown by the direct 
interaction of PC2 with a helix-loop-helix (HLH) protein Id2, which regulates cell proliferation 
and differentiation. Phosphorylation of PC2 by PC1 leads to its interaction with Id2. Id2 is found 
in a complex with another HLH protein, E47, which transcriptionally activates p21. Id2 lacks a 
nuclear localization signal and can be transported to the nucleus only through its interaction with 
E47 or some other proteins. Interaction of the Id2-E47 complex with PC2 sequesters this 
complex outside the nucleus. When PC2 is unable to bind to this complex, Id2 is translocated to 
the nucleus and it exerts its dominant negative effects on E47 and other HLH proteins. In this 
manner, normal expression of PC1 and PC2 leads to cell cycle arrest by an increase in p21, 
whereas a mutation in one of the polycystins leads to the dysregulation of this pathway resulting 
in increased cell proliferation (49). 
There are three proteolytic cleavage sites present on PC1. PC1 undergoes partial cleavage 
at the extracellular GPS domain, however, the N- and C-terminus of the protein remains non-
covalently linked. A missense mutation at the GPS domain, which makes PC1 non-cleavable has 
been reported in ADPKD in patients. Moreover, a mutant PC1 that cannot undergo GPS cleavage 
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was unable to rescue PC1-null cultured cells. This evidence suggests the requirement of PC1 to 
be cleaved at the N-terminal GPS domain to be fully functional. However, not all the PC1 
molecules in a cell are cleaved; they exist in a heterogenous population of full length and GPS 
cleaved isoforms (11, 34).  
Cleavage of PC1 in the C-terminal tail (CTT) which releases a soluble ~ 35kD fragment 
was described by Chauvet et al. This C-terminal cleavage suggested that PC1 may be involved in 
successive cleavage events similar to that of the regulated intramembrane proteolysis (RIP) 
pathway. In the RIP model described for various cell surface receptors such as Notch, APP, E-
cadherin, ErbB4 and CD44, the cytoplasmic segment of a transmembrane protein enters the 
nucleus after its activation and modulates gene expression, bypassing adaptor proteins and 
kinase/phosphatase cascades (35). Chauvet et al also showed that this nuclear translocation of the 
PC1 CTT leads to the activation of the AP-1 pathway. PC2 seems to keep PC1 CTT from not 
entering the nucleus since co-transfection experiments using full length PC2 and PC1 CTT led to 
the retention of PC1 CTT outside the nucleus and a reduction in AP-1 activity. PC2 is also 
required to interact with PC1 CTT to exert its inhibitory effect on PC1, since co-transfection 
experiments with a mutant PC2 which could not interact with PC1 CTT led to a reduction in AP-
1 activity. Unilateral ureteral ligation (leading to a reduction in fluid flow) and inactivation of the 
Kif3a gene (resulting in the loss of the cilia where polycystins are localized) in mice led to an 
increase in the nuclear translocation of PC1 CTT. These results showed that PC1 CTT cleavage 
and nuclear translocation are associated with the mechanosensory effects of cilia. A reduction in 
fluid flow or loss of fluid flow sensitivity in renal epithelial cells can lead to an accumulation of 
PC1 CTT in the nucleus and transcription of its target genes (35). PC1 with its long extracellular 
domain is assumed to detect fluid flow in renal epithelial cells and PC2 has an inhibitory effect 
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on the translocation of PC1 CTT. Hence, mutations in any of the polycystins can render renal 
epithelial cells insensitive to fluid flow and lead to the increased transcription of its target genes. 
Low et al described a more distal cleavage in the C-terminal domain of PC1 which 
generates a ~15-17kDa CTT fragment. The PC1 CTT fragment interacts with P100, a coactivator 
protein. The P100 protein has also been localized to the shaft and the basal bodies of renal cilia 
where PC1 is also present. P100 is overexpressed in the cyst-lining cells of ADPKD patients. 
The PC1 CTT fragment, together with P100, binds to the transcription factor STAT6 and leads to 
an enhancement of STAT6 dependent transcription. STAT6 is localized to the nucleus in MDCK 
and renal epithelial cells, however, subjecting cells to a constant flow of fluid (similar to the fluid 
flow in renal tubules) drastically changes the translocation of STAT6 from the nucleus to the 
primary cilia. Moreover, high levels of nuclear STAT6 were seen in the cyst-lining cells of 
ADPKD patients indicating that STAT6 dependent gene expression is upregulated in ADPKD. 
Under normal fluid flow conditions, PC1 keeps STAT6 sequestered to the cilia together with 
P100 preventing the transcription of P100/STAT6 genes. “No flow” conditions lead to the 
cleavage of the PC1 tail which translocates to the nucleus with P100 and STAT6 to mediate gene 
transcription. No flow conditions have been observed in renal injury as well as in the cysts of 
PKD. Dilated tubules in PKD also show decrease of fluid flow (50). 
A recent observation by Talbot et al shows the mechanism by which PC1 regulates STAT 
activity. Membrane anchored PC1 CTT activates STAT3, however, activation of STAT1 and 6 
requires soluble PC1 tail as well as a previous activation of these STATs by cytokine signaling 
(coactivation) (Figure 1-4 E-F). They found that STAT3, in addition to being activated by 
membrane-anchored PC1 CTT, can also be coactivated by the soluble PC1 CTT. The 
coactivation process can lead to an exaggerated cytokine response. STAT3 activity is highly 
  20
upregulated in ADPKD and PKD mouse models, while it is downregulated in normal renal 
epithelial cells after differentiation (51).  
The mTOR (mammalian target of rapamycin) pathway which regulates protein 
translation, cell proliferation and cell growth has been shown to be a target for PC1. Shillingford 
et al showed that PC1 CTT interacts with tuberin, the protein product of the TSC2 gene. 
Mutations in TSC2 lead to tuberous sclerosis which is characterized by the presence of 
hamartomas (benign tumor-like malformations) in multiple organs and renal cysts. Tuberin 
regulates the kinase activity of mTOR through a small GTPase, Rheb. Activated mTOR 
phosphorylates and activates its downstream effectors- S6K1, S6K2 (ribosomal kinases) and 4E-
BP1 and 4E-BP2 (eukaryotic initiation factor 4E-binding proteins) that leads to the stimulation 
of protein synthesis and proliferation. Shillingford et al also provided evidence for the increased 
activity of the mTOR pathway in the cyst-lining epithelial cells of ADPKD patients by showing 
an increase in activated phosphorylated mTOR and S6 kinase. Moreover, rapamycin, an 
immunosuppressant drug which is also a specific inhibitor of the mTOR pathway, was able to 
alleviate the cystic phenotype in two different PKD mouse models. These mouse models and a 
rat PKD model in which mTOR inhibition slowed the progression of PKD did not have a 
primary mutation in polycystin genes. This suggests that the activation of the mTOR pathway 
may be common to all renal cystic diseases despite their primary germ-line mutation (52, 53).  
In a recent report, Dere et al showed that PC1 regulates mTOR activity by altering the 
subcellular localization of tuberin. Suppression of mTOR by tuberin takes place only when 
tuberin is tethered to the membrane. Phosphorylation of tuberin by PI3K/AKT leads to its 
binding by 14-3-3 adaptor protein. This leads to the partitioning of tuberin to the cytosol thereby 
making it unavailable to bind with Rheb and its activating partner, TSC1. In the presence of a 
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functional membrane bound PC1 CTT, phosphorylation of tuberin by PI3K/AKT is inhibited. 
This leads to the tethering of TSC2 protein to the membrane and repression of mTOR signaling. 
In contrast, mTOR pathway is activated in the absence of a functional PC1 (52, 53).  
Wnt pathway modulation 
The Wnt signaling pathway, which is involved in embryonic induction, generation of cell 
polarity, cell proliferation and the specification of cell fate, is regulated by PC1. Wnts are 
secreted glycoproteins and canonical Wnt signaling regulates the cellular levels of a 
multifunctional polypeptide, β-catenin. The presence of Wnt ligands leads to the stabilization, 
accumulation and nuclear translocation of soluble β-catenin. Secreted Wnts bind to frizzled 
receptors on the cell surface, activating disheveled proteins and inhibiting glycogen synthase 
kinase (GSK-3β). Once inhibited, GSK-3 can no longer direct β-catenin for proteasomal 
degradation which leads to the accumulation and nuclear translocation of β-catenin. Once inside 
the nucleus, β-catenin interacts with the TCF/LEF family of transcription factors to regulate gene 
expression (34, 54, 55). 
Expression of stabilized β-catenin in renal tubular cells leads to the development of PKD 
in animals (54). Microarray analysis shows evidence for the activation of Wnt signaling in the 
cyst-lining cells of ADPKD patients (55). Experiments performed to demonstrate Wnt 
modulation by the PC1 C-tail has generated contradictory results. In contrast to previous 
experimental results which showed that the PC1 C-tail activates canonical Wnt signaling (54), a 
recent report suggest that PC1 C tail physically associates with β-catenin and acts as an inhibitor 
of intracellular Wnt signaling (55). Disparity between these results has been attributed to the use 
of membrane anchored PC1 CTT in the previous report versus the use of a soluble PC1 CTT in 
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the recent report. PC1 exerts this inhibitory effect on Wnt signaling pathway by reducing the 
apparent affinity of the interaction between β-catenin and TCF. The inhibitory effect of the PC1 
CTT on canonical Wnt signaling also adds up to the observation that the overexpression of c-
myc, a β-catenin/ TCF regulated oncogene, induces a renal cystic phenotype in transgenic mice. 
c-myc is also overexpressed in ADPKD and several other renal cystic diseases (55).   
Expression of a mutant PC2 in cell culture resulted in an increase in β-catenin protein 
levels. However, it is not certain whether this effect is mediated directly by the inactivation of 
PC2 or through an indirect effect that PC2 might have on PC1 (34).  
Non-canonical Wnt signaling, or the planar cell polarity pathway, has been implicated in 
PKD. Renal tubular cells generally divide parallel to the tubule axis. This oriented cell division 
(OCD) leads to the lengthening of the tubules. Loss of OCD leads to the division of cells at an 
angle perpendicular to the tubular axis leading to an expansion of tubule diameter rather than its 
elongation. Defects in OCD have been reported in several mouse models of PKD (56, 57). 
Additionally, Inversin, a protein product of the gene mutated in nephronophthisis type II (a 
disease characterized by renal cysts) was shown to act as a switch between canonical and non-
canonical Wnt signaling (58).   
These results suggest that the dysregulation of canonical and non-canonical Wnt 
signaling contribute to the pathogenesis of PKD.  
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How do cysts form in ADPKD? 
Cysts form as small dilations in renal tubules which then expand to form fluid-filled 
cavities of different sizes. Factors that are thought to lead to cystogenesis include a germ-line 
mutation in one of the polycystin gene alleles, a somatic second hit which leads to the loss of the 
normal allele and a third hit which can be anything that triggers the cell to proliferate more 
leading to the dilation of the tubules. Continued dilation of the tubules through increased cell 
proliferation, fluid secretion and separation from the parental tubule will lead to the formation of 
cysts. Other factors that are involved in cystogenesis and/or cyst progression include defective 
planar cell polarity, extracellular matrix abnormalities, inflammation, increased apoptosis, 
modifying genes and environmental factors (2, 36).  
Figure 1-4: Models for the functions of polycystins. A: PC1 and PC2 are found on the plasma 
membrane (PM) in this model. Activation of PC1 leads to the activation of PC2 which leads to 
calcium influx and changes in gene transcription. B: Polycystins signaling through the primary 
cilia. Renal cilia bend in response to fluid flow. Bending of the cilia leads to the influx of calcium 
through polycystins. C and D: Polycystins regulating G-protein signaling. Binding of PC1 to 
heterotrimeric G proteins activates the Gα subunit and the release of the βγ subunits. This leads to 
the activation of adenylyl cyclases and MAP kinases which can affect several cellular processes 
such cell proliferation, fluid secretion and differentiation. G protein signaling through polycystins 
can also affect the JNK/AP-1 and NFAT/AP-1 pathways. E: Polycystins signaling through the 
JAK-STAT signaling pathway. Membrane anchored PC1binds to JAK2 and activates it which 
then phosphorylates STAT3 resulting in its translocation to the nucleus. F: PC1 C tail can 
translocate to the nucleus and coactivate STAT1, 3 and 6 which were already activated 
independently through cytokine signaling. Once inside the nucleus, STAT transcription factors 
affect the expression of genes required for cell proliferation, cell growth, differentiation and 
apoptosis. G: Polycystins regulating the cell cycle through the JAK-STAT signaling pathway. 
PC1, in a reaction requiring PC2, activates JAK2 which leads to the phosphorylation of STAT1. 
Phosphorylated STAT1 translocates to the nucleus and activates the cyclin-dependent kinase 
inhibitor, p21. Activation of p21 results in the subsequent inhibition of cdk2 and cell cycle arrest. 
Redrawn from references 2 and 131. 
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There is controversy in the PKD field about some factors which are involved in the 
pathogenesis of PKD such as increased cell proliferation and defective planar polarity. The 
debate is whether they cause cystogenesis or just assist in making the cysts bigger thereby 
leading to disease progression. Recently, defective planar cell polarity was ruled out as an 
initiating mechanism for cystogenesis (discussed in detail below). Germ-line mutations that 
cause ADPKD are discussed in detail in a previous section. Other mechanisms which cause 
and/or promote cystogenesis are discussed below.  
The two-hit or second-hit model for cystogenesis 
Microdissection studies on ADPKD kidneys revealed a focal nature for cyst formation in 
patients. Even though each human kidney is formed of a million nephrons, only a few nephrons 
(~1000) form cysts in ADPKD patients. All the cells including renal tubular cells in ADPKD 
patients carry a germ-line mutation in one of the alleles of the polycystin genes. If the germ-line 
mutation itself is sufficient to cause cystogenesis, all these cells should form cysts. However, as 
mentioned above, cysts form only in a fraction of these cells. A second- hit theory was proposed 
to explain this phenomenon. This theory states that in addition to the germ-line mutation in one 
of the PKD1 or PKD2 alleles, a somatic mutation must occur in the other normal allele leading to 
the complete loss of function of the polycystins causing cyst formation. Cultured epithelial cells 
from the cysts of ADPKD patients showed loss of heterozygosity in two closely linked 
polymorphic markers located within the PKD1 gene in a subset of cysts. Further genetic analysis 
also confirmed the loss of the normal haplotype in this subset of cysts, thus favoring the second 
hit hypothesis (59).  
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Insights from mouse models 
A number of animal models have been described for ADPKD. A Pkd1-/- knockout mouse 
model was developed by homologous recombination leading to a frameshift mutation in exon 33 
of the Pkd1 gene. These mice die embryonically. Kidneys in the Pkd1-/- homozygous mice 
developed normally until E14.5. Cystic dilations were noted in the proximal tubules at E15.5 
which was followed by cysts crowding the entire medulla and most of the cortex in mice which 
survived to term. These results are consistent with the expression pattern of murine PC1 which 
peaks at E15.5. This shows the probable role of polycystins in tubular elongation and 
maintenance of tubular architecture rather than in nephron formation. Pancreatic duct dilations 
and hypoplastic lungs were some extrarenal manifestation seen in the Pkd1-/- mice (60).  
A Pkd2-/- knockout mouse model was also developed by targeting mutations into the 
murine Pkd2 locus. Similar to the Pkd1-/- knockout mice, the Pkd2-/- also showed normal 
kidney development until E14.5. Cysts began to form in the maturing kidneys by E15.5. Most of 
these mice died embryonically beginning at E16.5. These results suggested that similar to PC1, 
PC2 is not required for nephrogenesis but required for the proper maintenance and subsequent 
elongation of the nephron segments. Extrarenal manifestations such as cardiac defects and 
pancreatic duct dilations were also seen in these mice (61).  
Pkd1 and Pkd2 knockout mouse models show that the loss of both alleles of either of 
these genes is sufficient to cause PKD, hence validating the two-hit hypothesis in animal studies. 
However, results from Pkd1 transgenic mice which developed PKD in lieu of persistent 
expression of Pkd1, argue against the second hit theory (62, 63). Another mouse model, 
expressing a hypomorphic Pkd1 gene also developed PKD (64). These experimental evidences 
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suggest that the dysregulation of polycystins leads to cystogenesis rather than its loss or 
overexpression per se. 
A critical window for cystogenesis 
A study by Piontek et al (65) used a tamoxifen inducible Pkd1 mouse model which shed 
some light into the mechanism of cystogenesis. They inactivated Pkd1 in these mice at different 
time points during and after renal development. When they deleted Pkd1 in these mice at 
postnatal day 2 (P2) at a time when cortical nephrogenesis was still ongoing, these mice 
developed severely cystic kidneys within 2 weeks. They noted that the renal cortex in these 
cystic mice did not have any dysplastic or immature structures emphasizing the point that Pkd1 
is not required for the initial stages of nephrogenesis. However, when they inactivated Pkd1 in 
mice at 3 and 6 weeks of age, these mice did not develop PKD until approximately 5 to 6 months 
of age. In order to dissect out this time dependent phenotypic difference in cystogenesis, they 
inactivated the Pkd1 gene at several time points between P2 and P21. Mice which had Pkd1 
inactivated at P12 or before developed severe PKD within 3 weeks whereas inactivation between 
P14 and P21 induced a late cystic phenotype at 6 months of age. They observed an increase in 
cell proliferation rates in early stages (P12-P14) in normal control kidneys compared to normal 
controls at later stage (P14-P16). A microarray analysis of normal kidneys at ages between P11 
and P15 revealed that there is a differential change in gene expression between P11-P12 and 
between P14-P15. Most of the genes that were differentially expressed were clustered into 
transporter and catalytic functions. These results suggest that the rate of cyst development in 
these animals depends upon the developmental state of the kidneys at the time point when Pkd1 
is inactivated. These dramatic differences in phenotype between the inactivation of Pkd1 in 
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younger versus older mice also suggest that different pathways may be altered at these different 
time points leading to rapid cystogenesis earlier and slower cystogenesis later (65). 
A recent study by Grantham et al followed the diameter, volume and growth rates of 
cysts in eight ADPKD patients using CT and MR imaging methods for 3 years. All of these 
patients had normal renal function as measured by glomerular filtration rate. The rate of 
individual cyst growth in these patients ranged between -2.2 to 71.1% per year. Detection 
threshold for ultrasound imaging is 7 to 10mm whereas for CT and MR imaging methods it is 
2mm. Cysts as big as 10mm in diameter or larger have been detected in ADPKD children who 
are as young as 1 year old. Most of the cysts in ADPKD begin in utero in collecting ducts and an 
adult collecting duct varies in diameter from 40µm to 100µm as demonstrated by 
microdissection studies. Fetal collecting ducts are probably smaller than this. With this evidence 
in hand, Grantham et al questioned how fast the cysts should grow in utero in order to reach a 
size detectable by the imaging techniques (2-10mm) at birth or shortly thereafter. For a tubule as 
big as 100µm in diameter, the growth rate should be 20% per year to grow into a cyst of 2mm in 
diameter. Grantham et al reasoned that even though these numbers can be justified in an adult 
patient, this would not account for those 2mm cysts that can be detected in ADPKD children. 
This suggests the possibility that renal cysts that are formed in fetal life grow at a much faster 
rate in order to reach the detection threshold of the imaging techniques (18).  
The mouse model in which Pkd1 was inactivated between P2 and P12 and developed a 
rapid cystic disease show that cystogenesis and growth are sensitive to the developmental factors 
that dissipate approximately 2 weeks after birth in mice. Inactivation of the Pkd1 gene after this 
critical time window results in PKD which progress at a much slower pace. In mice, 
nephrogenesis and tubular elongation continues until 2 to 3 weeks of age which corresponds to 
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the window of time where they develop rapid cystic disease. In humans, on the other hand, 
nephrogenesis ceases at approximately 34 weeks of gestation. Renal cysts that are detectable by 
imaging techniques at birth or in young children with ADPKD may have grown exuberantly in 
the conducive fetal environment and thereafter, cyst expansion proceeds at a slower rate (18, 65).   
Third hit 
A more recent hypothesis has emerged in the ADPKD field, namely, the third hit for 
cystogenesis. This hypothesis is built upon the second hit hypothesis. The third hit theory states 
that a cell may not be cystogenic just because it received the first hit (germ-line mutation), and 
the second hit (somatic inactivation of the normal allele), but that it also requires a third hit 
which then leads to cell proliferation and cyst growth. The study by Piontek et al showed that 
late inactivation of the Pkd1 gene in adult kidneys resulted in a slow onset of cystogenesis in 
mice (65). Lantinga-van Leeuwen et al and Takakura et al also generated inducible Pkd1 mouse 
models in which they inactivated the Pkd1 gene in mature mouse kidneys (66, 67). Takakura et 
al reasoned that the slow onset of PKD when the Pkd1 gene was inactivated in adult animals 
could not be justified by the second hit hypothesis and proposed a third hit hypothesis. They 
stated that if the second hit was enough for cystogenesis, animals which had either the 
inactivation of both the germ-line Pkd1 alleles or the transheterozygous mice which had one 
germ-line Pkd1 mutation and loss of the other allele by inducible inactivation, should not take 
the length of time to develop cysts as was seen in these animals. The same group showed later 
that renal injury resulting from unilateral ischemia reperfusion injury accelerated PKD in the 
adult inducible Pkd1 knockout mouse model (68). Nephrotoxic injury and ischemia have been 
described as important stress events that cause a third hit (69, 70).  
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A similar phenotype as seen in the inducible Pkd1 knockout models was observed when 
genes required for primary cilia formation were inactivated in developing or adult kidneys. Patel 
et al described a study using an inducible mouse model to knockout the Kif3a gene, which is 
required for cilia formation. While Kif3a inactivation and loss of cilia at P2 led to PKD, 
inactivation of Kif3a at P10, P14 or P21 did not result PKD when followed 2 months after gene 
inactivation (57). The inducible knockout of another ciliary gene Ift88 in adult mouse kidneys 
also led to slow onset cystic disease. More recently, another third hit, unilateral nephrectomy, 
was added to the list by Bell et al. Unilateral nephrectomy leads to the hypertrophy of the 
remaining kidney and an increase in glomerular filtration rate as it compensates for the loss of 
the other kidney. As described above, mice which had lost renal cilia (as a result of the deletion 
of Ift88) in the adult kidney did not develop cystic kidneys until after 6 months. Bell et al 
inactivated Ift88 in mouse kidneys at 8 weeks of age, performed unilateral nephrectomy 1 week 
later and found that within 3 months they developed severe cystic kidney disease in their 
contralateral kidney. This was associated with hypertrophy which is a normal response when 
unilateral nephrectomy is performed. Activation of the mTOR pathway was also observed in 
these mice, as previously shown in association with unilateral nephrectomy-induced 
hypertrophy. Activation of mTOR pathway in these mice also led to increased cell proliferation 
which may have resulted in the rapid onset of cystic disease in these mice (69).  
Cell proliferation and fluid secretion 
Epithelial cell proliferation and fluid secretion are two hallmark features of ADPKD (71). 
Even the gross inspection of polycystic kidneys show increased epithelial cell proliferation 
evidenced by the increase in the circumference of the kidney tubules that form cysts. Renal 
tubules normally fall within a range of a few micrometers in diameter. However, in ADPKD, 
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renal tubules considerably increase in size so as to fall in a size range from millimeters to 
centimeters when they become cysts. Microscopic examination of polycystic kidneys shows the 
presence of large numbers of cells in the cyst wall epithelium (72). Several growth-stimulating 
factors such as the epidermal growth factor (EGF), the transforming growth factor α (TGF α) and 
the EGF receptor (EGFR) promote cell proliferation in PKD. Overexpression and mislocalization 
of EGFR to the apical side of the cystic epithelium has been reported in several animal models 
and in human PKD patients. Transgenic animals overexpressing TGF α also develop PKD (11).  
An important factor which leads to the proliferative phenotype in ADPKD is the second 
messenger, adenosine 3’, 5’ cyclic monophosphate (cAMP). cAMP is an intracellular mediator 
of adenylyl cyclase signaling and is shown to stimulate proliferation of cyst-lining cells in human 
PKD. The mammalian kidney is a target of several hormones such as arginine vasopressin 
(AVP), parathyroid hormone, secretin and vasoactive intestinal peptide as well as autocoids such 
as prostaglandins and adenosine, all of which lead to the elevation of the intracellular 
concentration of cAMP. In normal human kidneys, cAMP stimulation leads to a non-mitogenic 
response. However, ADPKD kidneys show a proliferative response to cAMP stimulation. cAMP 
mediates its effect in PKD by activating the B-Raf/MEK/ERK pathway. Moreover, normal 
human kidney (NHK) cells behave like ADPKD cells with a cAMP stimulatory phenotype when 
treated with calcium channel blockers. In contrast, the mitogenic response to cAMP was reversed 
in ADPKD cells when they were treated with calcium channel activators or calcium ionophores 
(16, 44, 73). 
During the early stages of cystogenesis, cysts are attached to their parental renal tubules 
and a derivative of the glomerular filtrate enters the cysts. Once these cysts expand to 
approximately 2mm in diameter, the cyst closes off from its parental tubule and now fluid can 
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enter the cysts only through transepithelial secretion. A transporter present in the basolateral 
membrane of cyst-lining cells, the Na-K-Cl-transporter, mediates the entry of chloride into the 
cytoplasm. Further entry of chloride into the cyst lumen is mediated by a chloride transporter 
present on the apical membrane of cystic epithelial cells, cystic fibrosis transmembrane 
conductance regulator (CFTR) (1, 11). The activity of CFTR increases in ADPKD possibly due 
to secondary effects from the increased concentration of cAMP (1). It has also been shown that 
patients who have cystic fibrosis and PKD have a milder disease (74).  
Other molecular abnormalities in ADPKD 
An increase in apoptotic DNA fragmentation and in-situ labeling of apoptotic cells was 
described in PKD patients and in two mouse models of PKD. Apoptotic cells were present in 
both cystic and non-cystic tubules as well as in glomeruli. The progressive loss of renal function 
seen in PKD may be explained by this increase in apoptosis.  Homozygous deletion of the anti-
apoptotic gene, Bcl-2, results in PKD in mice (7). ADPKD tissues also show an increase in the 
expression of c-myc. Moreover, kidney specific overexpression of c-myc in mice results in renal 
cysts characterized by both an increase in proliferation and apoptosis (11). 
Abnormalities in the innate immune system are another hallmark feature in both ADPKD 
and ARPKD. In ADPKD, accelerated production of monocyte chemotactic protein-1 (MCP-1) 
leads to an increase in mononuclear cells in the renal parenchyma. Abnormal urinary excretion 
of MCP-1 in early stage ADPKD patients shows that the immune system pathway is 
dysregulated during early stages of the disease. Analysis of the cpk mouse model which 
resembles human ARPKD, showed that around 60 monocyte/macrophage markers were 
overexpressed in the cpk mice. Genome wide transcription profiling in the cpk mouse model and 
  34
a rat model of PKD, Han:SPRD, showed an overexpression of macrophage markers and other 
innate immune factors. The expression pattern of one of these overexpressed macrophage 
markers, CD14, was analyzed in cpk mice, ADPKD and ARPKD patients. In the cpk mice, 
CD14 expression increased with increasing age in the controls and there was a significant 
increase in cystic kidneys compared to age-matched littermate controls. However, the number of 
CD14 positive mononuclear cells could not account for this increase in CD14 expression. Further 
histological analysis confirmed staining of CD14 in the proximal tubules and principal cells of 
collecting ducts and in cysts derived from these segments. Although CD14 is a membrane 
anchored receptor, once activated, soluble CD14 can be shed from the membrane. Both ARPKD 
and ADPKD patients showed an abnormal increase in the shedding of CD14. In ADPKD 
kidneys, these shed soluble forms of CD14 were washed out into the urine (75).  
CD14 is a potent stimulator of TNFα secretion which can lead to a cystogenic pathway. 
Shed forms of CD14 are also mediators for renal endotoxin-induced tubulointerstitial injury. An 
injury related CD14 overexpression is also seen in renal ischemia reperfusion injury animal 
models. CD14 is a major ligand for Toll-like receptor-4 (TLR4), through which it may 
transactivate cystogenic pathways such as signaling through Wnt, AP-1 and PI3K pathways (75). 
PC1 has been shown to be associated with the extracellular matrix (ECM) components 
and is thought to have a role in cell-extracellular matrix interactions. Owing to this role of PC1, 
alterations in the tubular basement membrane (TBM) including its thickening, splitting, fraying 
and multilayering have been seen in human PKD. Cystic kidneys from several animal models of 
PKD also show BM abnormalities including thickened and laminated basement membranes as 
well as increased expression of α1 type IV collagen and laminins β1 and β2 (76). A hypomorphic 
laminin α5 mouse model has also been shown to develop PKD (77). Speculation of PC1 working 
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as a receptor for extracellular matrix molecules and its expression in the basolateral surfaces may 
explain the PKD phenotype seen in the hypomorphic laminin α5 mutant. Moreover, recombinant 
PC1 peptides have also been shown to bind laminin in vitro. Increased EGF expression, an 
abnormality observed in PKD, may also be indirectly involved in modulating the effects of 
laminin since many of the laminin chains consist of multiple EGF- like repeats some of which 
even bind to the EGF receptor and signals downstream via this pathway (77).  
As mentioned in a previous section, polycystins by virtue of their location on the primary 
cilia of renal epithelial cells are thought to play a role in mechanosensation. In response to fluid 
flow and bending of the cilia, polycystins present on the cilia mediate the entry of calcium into 
cells. Pkd1-/- renal epithelial cells, have normal primary cilia, however, they lack the flow-
induced calcium response of normal cells (43). Mutations in any of the polycystins as it occurs in 
ADPKD, leads to abnormalities in the fluid-flow sensing mechanism which may contribute to 
cyst development. A kidney specific inactivation of Kif3a, a subunit of kinesin-II that is essential 
for cilia formation, inhibited renal ciliogenesis and resulted in a subsequent development of PKD 
in mice (78).  
Defective planar cell polarity is another hallmark feature seen in PKD. This phenotype 
can also be attributed to the presence of cystoproteins in cilia. It has been proposed that cilia in 
the developing kidney are responsible for the oriented cell division (OCD) along the length of a 
renal tubule. Loss of OCD was observed during advanced stages of cystogenesis in the pck rat, 
an orthologous model of ARPKD. Measurement of mitotic angles in the pck rat showed that the 
loss of OCD preceded tubular dilation in these animals. Kidney specific inactivation of HNF1β, a 
transcription factor involved in the regulation of expression of Pkd2 and Pkhd1, also resulted in 
PKD as a result of severe mitotic angle distortion and loss of OCD seen even at birth (56). 
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However, recent results with the kidney specific inactivation of Pkd1, Pkd2 and Pkhd1 mouse 
models show that loss of OCD is not required for cystogenesis. Precystic tubules from 
conditional Pkd1 or Pkd2 mice did not show the loss of OCD.  Loss of OCD was observed once 
the tubules dilated to form cysts. The conditional deletion of Pkhd1 specifically in the kidneys 
resulted in the loss of OCD, however, these mice did not develop PKD (79).  
ADPKD is a fully penetrant trait. Virtually 100% of all individuals who inherit one of the 
mutated polycystin genes will develop PKD in their lifetime. The disease presentation and 
severity, however, vary among ADPKD patients, even within family members (2). This 
phenotypic variability associated with disease presentation led to the investigation of modifying 
loci and environmental factors that may influence disease progression. Although ADPKD is a 
single-gene disorder, the disease phenotype is a complex trait. In single-gene disorders with 
complex traits, the primary mutant gene product is embedded in a complex system that includes 
genetic modifiers and modulating environmental factors (80). 
Belibi et al tested the effects of caffeine on normal and ADPKD cultured cells. Caffeine 
inhibits phosphodiesterases (PDE), the enzymes which hydrolyze cAMP thereby leading to the 
accumulation of this second messenger. As mentioned previously, increased cAMP levels can 
result in a mitotic response in the ADPKD cells. This study found that caffeine and other PDE 
inhibitors such IBMX and rolipram increased intracellular cAMP levels in ADPKD cells (81). 
Therefore, caffeine is an important environmental influence in the progression of ADPKD which 
patients should avoid.  
Early onset of PKD is seen in patients with microdeletions in the PKD1 and the TSC2 
genes which are present on the same chromosome adjacent to each other (82, 83). Bilineal 
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inheritance of heterozygous PKD1 and PKD2 mutations also lead to severe renal disease in some 
patients (83). Transheterozygous mutations in the Pkd1 and Pkd2 genes in mice has also been 
reported to have a greater than additive renal disease phenotype. Moreover, patients who have 
cystic fibrosis and PKD have a milder disease (74). 
The possible existence of modifier genes in ADPKD patients was also confirmed from an 
analysis carried out in monozygotic (MZ) twin siblings. Large intrafamilial variability was 
observed in the progression of renal disease in these MZ twins (84). 
 
 
 
Figure 1-5: Various mechanisms of cystogenesis and disease progression in 
ADPKD  
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Genes that modify PKD phenotype 
Pax2 is a developmentally regulated gene which is required for the differentiation and 
proliferation of the renal epithelium in both mice and humans. Expression of Pax2 is seen in the 
nephric duct, ureteric bud and induced mesenchyme in the normal developing kidney. Pax2 is 
expressed in the nephrogenic zone of the kidney from E11 to postnatal day 10 in mice (85). Pax2 
null mice lacked the urogenital system including absent kidneys and ureters whereas 
overexpression of Pax2 led to multicystic disease (86). Human juvenile cystic kidneys, ADPKD 
kidneys and cpk (a mouse model which resembles ARPKD) mouse kidneys show persistent 
expression of Pax2 (85). 
Expression of Pax2 during kidney development and in cystic kidneys prompted two 
independent groups of investigators to ask the question if Pax2 is involved in cystogenesis. 
Ostrom et al showed that reduced gene dosage of Pax2 can modify the cystic phenotype in the 
cpk mouse model of PKD. Mice homozygous for the cpk mutation and heterozygous for the 
Pax2 mutation had reduced cystic severity and a longer life span (85).  
The role of Pax2 in cystogenesis was also investigated in the Pkd1 null mice. Fetal 
kidneys (E18.5) from the Pkd1 null mice showed the presence of Pax2 in the cystic epithelium, 
bifurcating ureteric buds, and also in the condensing mesenchyme. Double mutant mice which 
were Pkd1 null and heterozygous for the Pax2 mutation (Pkd1-/-;Pax2+/-), showed a marked 
reduction in kidney mass and cyst size when compared to Pkd1-/-;Pax2+/+ mice (86).  
The role of another developmentally regulated gene, Cux1, was also investigated in PKD. 
Cux1 is a homeobox gene important during renal development. Cux1 is also ectopically 
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expressed in several mouse models of PKD as well as in human ADPKD kidneys. A mutation in 
Cux1 modified cyst progression in the cpk mouse model of PKD (87).  
The Cut family of proteins 
Cux1 (Cut homeobox 1) is a murine homologue of the Cut homeobox gene in Drosophila 
melanogaster (88). Homeobox genes encode homeodomains which are 61 amino acid long DNA 
binding domains. The homeodomain was the first protein domain that was discovered in 
Drosophila embryonic development and later through sequence comparison found to be 
conserved among higher eukaryotes. Mutations in the homeobox genes in Drosophila result in 
“homeotic transformations”. Homeotic transformation is a developmental anomaly where one 
body part transforms into and acquires the characteristics of another body part (89, 90).  
Several mutations have been described in the Drosophila Cut locus. Embryonic lethal 
mutations in the Cut locus fall into two complementation groups, lethal I and lethal II. These 
mutations result in the transformation of the external sensory (es) organs into internal sensory 
(chordotonal, ch) organs (90-92). Viable mutations in the Cut locus result in morphological 
changes in the wings (cut wing, ct) or the legs (kinked femur, kf) (93). The locus was named Cut 
after the “cut wing” phenotype.  
Cut proteins are expressed in the insect excretory organs, Malpighian tubules. Malpighian 
tubules serve as primitive kidneys in Drosophila. Some mutations in the Cut locus result in the 
transformation of Malpighian tubules into gut tissue showing that the Cut proteins are required 
for the proper development of Malpighian tubules (94).  
A human homologue of Cut, CDP (CCAAT displacement protein) or CUTL1 (Cut-like 
1), was first purified from HeLa cells (95, 96). As the name implies, CDP acts as a 
  40
transcriptional repressor by preventing the binding of positively acting CCAAT transcription 
factors to promoters (95). The human CUTL1 gene is a candidate tumor suppressor gene present 
on chromosome 7q22. This region is frequently rearranged or deleted in uterine leiomyomas, 
acute myeloid leukemia and myelodysplastic syndrome. Other mammalian homologues of Cut 
include Clox (dog) and CDP2 (rat) (88). Another Cut family member, Cux2, has also been 
described in mice. Cux2 is exclusively expressed in the nervous system (96). The Human 
Genome Organization (HUGO) has recently changed the nomenclature of Cut genes and proteins 
to Cux1 (gene) and Cux1 (protein) to describe the mouse counterparts and CUX1 (gene) and 
CUX1 (protein) to describe the human homologues (97). 
There are five evolutionarily conserved domains in the Cut proteins. These include a 
region which will form a coiled-coil structure, three Cut repeats and the Cut-Homeodomain (HD) 
(98). The homeodomain is encoded by the homeobox found on the C- terminal region of the 
protein. The Cut repeats (CR) are stretches of 60-70 amino acids which have 55-68% amino acid 
identity and are known as CR1, CR2 and CR3. Cut repeats also have 59-64% nucleotide identity 
suggesting their origin from a duplication event (90, 93, 98). Murine and human homologues of 
Cut proteins have two repression domains located at the carboxy-terminal region (99, 100). 
These repression domains in human Cut proteins map to two subdomains of 81 and 29 amino 
acids. They independently repress gene expression from activated promoters (Figure 1-6) (100). 
 
 
 
 
  41
 
 
 
 
 
Cut proteins are believed to function as transcription factors in flies and mammals. 
Accordingly, they have been localized to the nucleus in both species (100). In mammals, Cut 
proteins were primarily characterized as transcriptional repressors. However, recent evidence 
indicates that Cux1 can act as transcriptional repressors or activators. Cux1 is capable of binding 
to a wide range of DNA sequences including CCAAT, ATCGAT, Sp1 sites and AT-rich matrix 
attachment regions. Evaluation of the DNA binding mechanism of Cut proteins revealed that Cut 
repeats cannot bind DNA as monomers. However, combinations of domains such as CR1CR2, 
CR3HD, CR1HD and CR2HD exhibit high DNA binding affinities. The CR1CR2 dimer showed 
rapid on-off rates and hence transient DNA binding, while CR3HD showed slow and stable 
DNA binding. The CCAAT displacement activity of Cut proteins involve the CR1CR2 domains 
and the homeodomain is not involved in this process (98).  
 Transcriptional repression by Cux1 is mediated by two different mechanisms. The first 
mechanism involves passive repression where these proteins compete with activators such as Sp1 
or CCAAT -binding factor for binding sites on the DNA. The second mechanism involves active 
repression where Cux1 binds to DNA with its repression domains at a large distance from the 
Figure 1-6 Structure of Cut proteins. The N-terminal domain of Cux1 has an inhibitory 
domain whereas the C-terminus has two repression domains. These proteins also have a 
coiled coil domain, three Cut repeats and a homeodomain. Redrawn from reference 97. 
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transcription start site of the gene. Cux1 binds to DNA in this manner through DNA looping (99, 
100). 
The transcriptional repression targets of Cut homologues include γ-globin, c-Myc, myosin 
heavy chain, NCAM and CD8a, c-mos, MMTV long terminal repeats, gp91-phox, HNP, C/EBP 
epsilon, lactoferrin Rnf35, p21 and p27 genes (97, 101).  
Regulation of Cux1 
Transcriptional regulation of Cux1 
Regulation of Cut by the Notch and Wingless signaling pathways have been described for 
cell-type specification during Drosophila wing development (99). Downregulation of Cut by 
Notch was also shown in Drosophila oogenesis (102). During mouse embryonic development, 
co-expression of Cux1 and Notch signaling pathway components is seen in multiple tissues. 
Most of these tissues co-expressed Cux1 with the Notch receptors 1 or 3 and the Notch pathway 
ligand Jagged1. In the developing kidney, Cux1 is co-expressed with Notch pathway components 
in the condensing mesenchyme, comma and S-shaped bodies and in the presumptive podocytes 
of capillary loop stage glomeruli. Cux1 was also significantly upregulated in a rat kidney 
epithelial cell line, RKE which constitutively expressed Notch1. This increase in Cux1 
expression correlated with the decrease in the expression of a cyclin dependent kinase inhibitor 
(CKI) p27, a transcriptional repression target of Cux1 (103). A direct interaction between Cux1 
and Grg4 (Groucho 4), an effector of Notch signaling pathway has also been shown (104). 
CUX1 was also shown to be a transcriptional target of transforming growth factor β 
(TGFβ), a major modulator of tumor cell migration. In various tumor cell lines, CUX1 activity 
was associated with an increase in migration and invasiveness both in vivo and in vitro. CUX1 
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was identified as the mediator of pro-migratory effects of TGFβ. Transcriptional upregulation of 
CUX1 by TGFβ leads to the activation of a transcriptional program regulating genes involved in 
cell motility, invasion and extracellular matrix composition (105).  
Post-translational regulation of Cux1 
Post-translational modifications of Cux1 include phosphorylation, dephosphorylation, 
proteolytic processing and acetylation (Figure 1-7) (97). Both Casein kinase II and protein kinase 
C (PKC) phosphorylate Cux1 at serine/ threonine residues within the cut repeats (97, 106, 107). 
Protein kinase A (PKA) phosphorylates Cux1 at a serine in the linker region between CR3 and 
HD (97, 108). Cyclin A/ Cdk2, the principal cyclin-cdk complex during S phase, interacts with 
Cux1, however, Cux1 is not phosphorylated by this complex. As the cell moves out of S phase 
into G2 phase, Cyclin A/ Cdk1 becomes the main cyclin-cdk complex which phosphorylates 
Cux1 in the linker region between CR3 and HD and also within the homeodomain (97, 109).  
 
 
 
 
Figure 1-7 Post-translational modifications of Cux1. Casein Kinase II (CKII), Protein 
Kinase C (PKC) and Protein Kinase A (PKA) phosphorylate Cux1 at different sites. CKII and 
PKC phosphorylate Cux1 in all three Cut repeats. CyclinA/Cdk1 complex also phosphorylate 
Cux1 in the linker region between CR3 and HD and also in the HD. Cux1 is dephosphorylated 
by Cdc25A and acetylated by PCAF in the CR3HD region. Cleavage sites for the nuclear 
form of Cathepsin-L is found in the linker region between CR1 and CR2. Caspases also 
proteolytically process Cux1 and two caspase cleavage sites are found on the first repression 
domain. Redrawn from reference 97. 
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Acetylation occurs at conserved lysine residues around the HD region of Cux1, mediated 
by PCAF acetyl-transferase. Cdc25A phosphatase dephosphorylates Cux1 at the CR3HD region 
which leads to an increase in DNA binding at G1/S transition. Acetylation and phosphorylation 
events negatively regulate Cux1 by causing an inhibition in DNA binding and transcriptional 
regulation. In contrast, dephosphorylation events lead to an increase in DNA binding (97).   
Proteolytic processing of Cux1 is carried out by a nuclear form of cathepsin-L and 
caspases which generate various short isoforms of Cux1 (Figure 1-8) (97).  
Cux1 Isoforms 
Cux1 isoforms exhibit distinct DNA binding and transcriptional properties. These 
isoforms are known by their apparent molecular weights. Cux1 exists in its full length form, 
p200, during early G1 phase. Full length Cux1 cannot stably bind to its consensus target 
sequence. As the cell progresses into S phase, Cux1 gets processed into a shorter isoform p110, 
that can stably bind DNA (110). The p110 isoform lacks the N-terminal inhibitory domain and 
the first Cut repeat (110, 111). Processing of p200 Cux1 to form p110 is carried out by a cysteine 
protease, cathepsin-L. Cathepsins are lysosomal proteases, however, an isoform of cathepsin-L is 
localized to the nucleus during the G1/S transition of cell cycle and proteolytically processed the 
p200 Cux1 to form the 110kDa Cux1 (112).  Another shorter Cux1 isoform, p90 is also 
generated during the G1/S transition by cathepsin-L cleavage (97, 110). A C-terminally truncated 
Cux1 isoform, p150 is generated which is incapable of binding DNA. It is not known what 
proteolytic event generates this isoform. The p150 isoform functions in a dominant negative 
manner in the lactating mammary gland (97, 113). Two processing events mediated by 
cathepsin-L and caspases generate a p80 isoform of Cux1 (97, 111).  A 55kDa isoform of Cux1 
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is present in mouse testis (114). Transcription initiation within intron 20 of Cux1 gene generates 
a shorter isoform of Cux1, p75 which contains only two domains, CR3 and HD. The p75 isoform 
stably binds DNA and can act as both a transcriptional repressor of p21 and a transcriptional 
activator of DNA polymerase α (115).  
 
 
 
 
 
 
 
Figure 1-8 Cux1 isoforms. Various isoforms of Cux1 are named according to their apparent 
molecular weights.  The full length Cux1 is p200. Proteolytic processing by Cathepsin-L and 
Caspases generate p150, p110, p90 and p80 isoforms. The p55 isoform is present in the testis. 
Alternate transcription initiation at a start site in intron 20 generates the p75 isoform.  The p200 
isoform acts only as a transcriptional repressor whereas the p75, p80, p90 and p110 isoforms 
can function as repressors or activators depending on the promoter. The p150 form is known to 
function in a dominant negative manner. Redrawn from reference 97. 
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Role of Cux1 in cell cycle regulation 
The cell cycle is broadly divided into two stages- interphase and mitotic phase. Mitotic 
phase involves cell division and is characterized by different stages known as prophase, 
metaphase, anaphase and telophase. Interphase is the interlude between two mitotic phases. 
Interphase is divided into 3 different stages known as G1, S and G2 phases. The cell is prepared 
for DNA synthesis in G1 phase, DNA replication occurs in S phase and G2 phase prepares the 
cell for the upcoming mitosis. Cells in G1 phase can stay in a resting state known as G0 before 
committing to enter into DNA replication (116).  
Correct cell division is ensured by tight control of the cell cycle through a variety of 
mechanisms. Transition of cells from one phase to the next is controlled by a set of different 
cellular proteins (Figure 1-9). These include cyclins, cyclin dependent kinases (CDK) and cyclin 
dependent kinase inhibitors (CKI). Specific cyclin-CDK pairs are activated at specific points of 
the cell cycle (116). The active complex formed between cyclins and CDKs will phosphorylate 
the retinoblastoma protein (Rb) which is usually bound to the transcription factor E2F. 
Phosphorylation of Rb releases E2F which in turn activates genes required for DNA synthesis 
(117). CKIs are cell cycle inhibitory proteins which counteract the activity of CDKs either by 
binding to a particular CDK or binding to the CDK-cyclin complex. Two distinct families of 
CKIs are known, the INK4 family and the CIP/KIP family. The INK4 family of inhibitors 
specifically inactivates the G1 CDK-cyclin complex and includes p15, p16, p18 and p19. The 
CIP/KIP family of inhibitors works by inhibiting the G1 CDK-cyclin complex thereby regulating 
G1-S transition and also by inhibiting the CDK1-cyclinB complex during mitosis to a lesser 
extent. The CIP/KIP family includes p21, p27 and p57 (116). p21 and p27 are transcriptional 
repression targets of Cux1 (101, 118).  
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In Drosophila, Cut proteins are known to be involved in cell type specification during 
cellular differentiation. The role of mammalian Cut proteins in the cell cycle was first shown by 
their ability to downregulate the CKI, p21 (118). Later it was also shown that Cux1 can repress 
another CKI, p27, in mammalian kidneys (101). 
Figure 1-9 Cell cycle regulation. Upon receiving a stimulus to divide, cells enter the cell 
cycle which is characterized by two main phases- the interphase and the mitotic phase. 
Interphase is characterized by DNA replication and preparation of the cell to divide into two 
before the mitotic phase.  After mitosis, cells that do not divide further will stay in a quiescent 
state in the G0 phase. Positive and negative regulation of the cell cycle is shown in the figure 
which is carried out by the cycin/ cyclin dependent kinase (CDK) complexes and the cyclin 
dependent kinase inhibitors (CKI- CIP/KIP and INK4). As shown, there are specific 
cyclin/Cdk complexes and CKIs for different phases. INK4 inhibitors mainly inhibit the 
G0/G1 transition whereas the CIP/KIP inhibitors are more promiscuous inhibitors.  
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The DNA binding activity of mammalian Cut proteins is regulated in different phases of 
the cell cycle. During G0 and early G1 phases, Cut DNA binding activity is very weak unless the 
cell extracts were previously treated with alkaline phosphatase. Strong DNA binding is seen in S 
phase which is associated with the dephosphorylation of Cut proteins by Cdc25A phosphatase. 
Overexpression of Cdc25A phosphatase triggers the G1-S transition in cell cycle (110, 118). The 
increase in the activity of Cux1 also results in the downregulation of p21. Cux1 repressed the 
p21 promoter reporter activity in cotransfection experiments whereas an antisense Cux1 vector 
Figure 1-10 Cux1 in cell cycle. Full length p200 Cux1 is highly expressed during the G1 
phase. Cdc25A phosphatase that is expressed highly during the G1/S transition 
dephosphorylates Cux1 and increases its DNA binding. The p200 Cux1 binds DNA 
transiently and transcriptionally represses the CKIs, p21 and p27. By repressing the 
expression of these inhibitors, Cux1 drives the cell forward into S phase. Near the end of the 
G1/S transition, there is an increase in the expression of the nuclear form of Cathepsin-L 
which cleaves Cux1 to form the p110 isoform which transcriptionally activates the genes 
required for DNA synthesis in S phase such as DNA polymerase α, DHFR, Cyclin A and 
CAD.  
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restored p21 expression (110). These events are carried out by the full length p200 Cux1 which 
rapidly binds DNA (119). 
The p110 isoform is generated as cells progress into the S phase of cell cycle by the 
increase in expression of nuclear cathepsin-L which subsequently cleaves p200 Cux1. Unlike the 
p200 isoform, p110 can act both as a transcriptional repressor or activator depending on the 
promoter context (119). Cux1 was previously shown to be the DNA binding subunit of the 
promoter complex, histone nuclear factor-D (HiNF-D) which interacts with several cell cycle 
regulatory elements of histone genes during the G1/S transition of cell cycle. Several genes 
which are upregulated during S phase were found to be transcriptionally activated by p110 Cux1. 
These genes include DNA polymerase α, cyclin A, dihydrofolate reductase (DHFR) and 
carbamoyl-phosphate synthase-aspartate carbamoyltransferase-dihydrorotase (CAD). The full 
length Cux1 was unable to carry out these transcriptional activation functions. Later, during G2 
phase, DNA binding of Cux1 decreases owing to its phosphorylation by cyclin A or Cdk1 within 
the homeodomain (120). 
Role of Cux1 in Kidney development 
Cux1 is expressed in the developing brain, limb, lung and kidney during mouse 
embryogenesis. High expression of Cux1 can be seen in the metanephric kidney shortly after 
metanephric induction and it remains high until the completion of nephrogenesis. Cux1 
expression decreases after nephrogenesis and adult kidneys show very low levels of Cux1. In situ 
hybridization shows high Cux1 expression in the nephrogenic zone of the kidney in uninduced 
and condensed mesenchyme and also in developing epithelial structures such as ureteric bud, 
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renal vesicles and S-shaped bodies. By the end of nephrogenesis, Cux1 is downregulated and 
only low levels of it can be detected in the mature tubules and glomeruli (101). 
Studies using CMV/Cux1 transgenic mice which overexpressed the Cux1 gene under the 
control of CMV promoter revealed the role of Cux1 in cell cycle and its regulation. The 
transgenic mice showed multiorgan hyperplasia including kidney hyperplasia. The CKI p27 was 
found to be downregulated in the developing kidneys of these mice (101). Increased expression 
of Cux1 in mesangial cells resulted in mesangial cell expansion and cell proliferation. The 
overexpression of Cux1 also resulted in the development of glomerulosclerosis, interstitial 
fibrosis and proteinuria (121). Cux1 transgenic mice developed hepatomegaly which correlated 
with increased cell proliferation. Ectopic expression of Cux1 was limited to a population of small 
cells in the transgenic livers but not in mature hepatocytes. Many of these small cells also 
expressed markers of cell proliferation (117).  
Several Cux1 knockout mouse models have been generated. One of these includes a 
knockout in which Cux1 lacked the first Cut repeat (Cux1tm1Ejn or Cux1ΔCR1). Wavy hair and 
curly whiskers were observed in these mice. Impaired lactation was observed in homozygous 
females which resulted in ~50% postnatal lethality in their litters. These mice had phenotypically 
normal kidneys (97). Another knockout mouse model was generated with a C-terminal deletion 
of the protein which included the homeodomain and repression domains (Cux1ΔHD). The 
resulting knockout mice have a complex phenotype such as partial neonatal lethality, stunted 
growth, wavy fur and whiskers and latent alopecia. These mice also showed muscle wasting with 
loss of body fat similar to cachexia. The complexity in the phenotype can be attributed to the role 
of Cux1 in the transcriptional regulation of multiple target genes (122). Luong et al generated a 
similar knockout mouse line in which the homeodomain and the C terminus of the Cux1 protein 
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were genetically deleted (Cux1ΔC). This mutation led to decreased immune function, 
hyperplasia of myeloid cell lines, abnormal formation of the hair fibers and reduced fertility 
(123). The mutant protein in both Cux1ΔHD and Cux1ΔC mice localize to the cytoplasm 
indicating the loss of nuclear localization of Cux1. Therefore, homozygous Cux1ΔHD and 
Cux1ΔC mice have a functional loss of Cux1 (122, 123).  
Role of Cux1 in PKD 
Cux1 expression was examined in the cpk mouse- a mouse model that resembles human 
ARPKD. Cystogenesis in cpk mice starts at E17 and affected mice die of uremia by 3-4 weeks of 
age. Cux1 was found to be highly expressed in the cyst epithelium in 21 day old mice (late stage 
cystogenesis) but not in phenotypically normal littermates. The increase in Cux1 resulted only in 
a slight increase of mitotic activity in the polycystic kidneys of these mice compared to the 
kidneys of normal mice. However, cyst epithelial cells remained highly undifferentiated. 
Therefore, the overexpression of Cux1 in these cysts correlated better with the absence of 
cellular differentiation than increased cellular proliferation (88).   
Cux1 expression was also evaluated in a Pkd1 null mouse model, a model for ADPKD. 
Cux1 was highly and ectopically expressed in both cystic and normal tubules in the cystic 
kidneys from early and late stage Pkd1 null embryos. This also correlated with increased cell 
proliferation since both Cux1 and PCNA (a cell proliferation marker) co-localized in cells lining 
the cysts. A decrease in p27 expression was seen during late stages of cystogenesis. In the 
kidneys of cpk mice, Cux1 upregulation was not observed until late stages of cystogenesis. 
Whereas no p21 was detected in the Pkd1 null embryo kidneys, Cux1 and p21 were co-localized 
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in cyst lining cells in the cpk mice. These cystic cells also showedan increased incidence of 
apoptosis (124).  
The levels of the full length, p200 Cux1, were increased in human ADPKD kidneys 
compared to normal human kidneys. A decrease in the nuclear form of Cathepsin-L was also 
seen in the ADPKD kidneys. A decrease in Cathepsin-L resulted in a reduction in the proteolytic 
processing of Cux1, resulting in the accumulation of p200 Cux1 which transcriptionally 
represses p21 and p27 thereby increasing cell proliferation (87).  
The p75 isoform of Cux1 was observed to be overexpressed in Pkd1-/- polycystic 
kidneys. Sustained expression of p75 Cux1 in transgenic animals resulted in renal cystogenesis 
in a dosage-dependent manner. Cysts were observed by 12-18 months of age in these mice. 
Increased proliferation was observed in cyst lining cells of these mice. The rate of apoptosis was 
normal. At a molecular level, these mice showed downregulation of p27 and upregulation of c-
Myc (125).  
Cux1 as a modifier of the PKD phenotype 
An ARPKD mouse model carrying a targeted mutation in the Cux1 gene was generated to 
determine the role of Cux1 in the progression of PKD. The cpk mouse model that resembles 
human ARPKD was crossed to Cux1tm1Ejn. This Cux1 mutant mouse carried an in-frame deletion 
of Cux1 that spanned exons 15 and 16. The phenotype of Cux1tm1Ejn included wavy hair and 
curly vibrissae. Mutant females had a lactation defect and were unable to support pups. The 
kidneys of these mice were phenotypically normal. The Cux1tm1Ejn phenotype was similar to the 
mutations in the EGFR pathway. Genetic or pharmacologic inhibition of EGFR activity had been 
shown to result in decreased cyst formation and improved kidney function. The Cux1tm1Ejn mice 
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were crossed with Cys1cpk mice anticipating a similar alteration in cyst progression. The double 
mutant mice indeed showed a modification in cyst progression. However, the mutation in Cux1 
did not reduce the cyst progression as expected, rather it accelerated the disease progression in 
these animals. This phenotype was explained by the ectopic expression of Cux1ΔCR1 (the 
truncated form of Cux1) protein in the double knockout mice which in turn repressed p21 and 
p27 thereby increasing cell proliferation resulting in a rapid progression of the disease (87).  
A regulatory loop between Cux1 and Polycystin-1 
Cux1 regulates cell cycle by inhibiting p21 and p27 CKIs. Cux1 transgenic mice which 
overexpressed Cux1 had multiorgan hyperplasia including renal hyperplasia. This phenotype was 
similar to that of the p27 knockout mice which also showed kidney hyperplasia. Both mRNA and 
protein levels of p27 were downregulated in Cux1 transgenic mice. Moreover, promoter reporter 
assays showed repression of the p27 promoter by Cux1 (101, 126).  
A study by Bhunia et al placed polycystins in direct control of the cell cycle. They 
showed that PC1 binds to JAK2 which then phosphorylates STAT1 and 3 leading to the 
inhibition of the CKI, p21. Another study by Li et al showed that PC2 interacts with an HLH 
protein Id2 and regulates the cell cycle. Both of these studies suggested that polycystins act to 
induce cell cycle arrest by activating p21 (48, 49) (model shown in Figure 1-5 G). However, 
unlike the p27 knockout mice which showed a renal hyperplasia phenotype, the p21 knockout 
mice did not show any striking phenotype. No renal hyperplasia was observed in these mice 
(127).  
A more recent observation by Talbot et al also provided evidence that both membrane-
anchored and soluble PC1 C-terminal tails can regulate STATs 1, 3 and 6 (51). Research in the 
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obesity field shows that cathepsin-L, a proteolytic enzyme which generates shorter isoforms of 
Cux1, is regulated by STAT3. Moreover, this study also places Cux1 in a ciliary assembly 
function (128). ADPKD cells show an increase in the accumulation of full length p200 Cux1 
which is correlated with a decrease in cathepsin-L levels (87). This evidence shows that Cux1 
may be regulated by the polycystin complex (Figure 1-11). 
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Figure 1-11 A regulatory loop between Cux1 and Polycystin-1 A: In a normal person who 
does not have ADPKD, polycystins are normal and through the JAK-STAT pathway p21 is 
upregulated and cell cycle arrest takes place in differentiated cells. Cathepsin-L processes the 
full length p200 Cux1, which also leads to a decrease in the CKIs p21 and p27 which leads to 
cell cycle arrest. B: In a person with ADPKD, polycystin function is abnormal owing to the 
mutations in the PKD1 or PKD2 genes. Also, cathepsin-L levels are decreased in these 
patients leading to the accumulation of the p200 Cux1. Defects in both these pathways lead to 
an increase in cell proliferation. A role for STAT3 in regulating cathepsin-L has been shown. 
PC1 is also shown to regulate STAT3 signaling. Therefore, Cux1 maybe directly regulated by 
PC1 through STAT signaling. This may lead to an exaggerated cell proliferation response in 
ADPKD patients.  
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Goals of this study 
Approximately 600,000 individuals in the U.S and 6-10 million worldwide suffer from 
ADPKD. The disease leads to End-Stage Renal Disease (ESRD) in most patients (1). A recent 
study evaluating renal function and healthcare costs in PKD patients found that the total 
healthcare costs rose precipitously in patients who had an eGFR (estimated glomerular filtration 
rate) less than 30ml/min. Therefore, strategies that prevent renal dysfunction in these patients can 
also help to reduce their healthcare costs significantly (129).  
At present, there are no specific treatments available to treat ADPKD patients. Rather, the 
current treatment strategies are focused on addressing symptoms such as hypertension and using 
dietary modifications to delay the process of ESRD. Several clinical trials are underway which 
target different aspects of the disease.  
Increased cell proliferation is a prominent feature in ADPKD, leading to cystogenesis and 
modification of the disease progression. Thus, identifying molecular mechanisms underlying the 
cell proliferative defects in ADPKD may provide therapeutic targets for the treatment of the 
disease. Cux1, being a very important gene in renal development as well as in cell cycle 
regulation, (both features important in PKD) makes it a very good candidate to study in PKD.  
Even though Cux1 is ectopically expressed in various mouse models and in human 
ADPKD patients, overexpression of Cux1 in mice did not result in PKD (101). This suggests that 
overexpression of Cux1 by itself is insufficient to develop PKD. In this particular study, we 
sought to determine if Cux1 is required to develop PKD in an ADPKD mouse model. The central 
hypothesis is that the deregulation of Cux1 is required for the cell proliferation defects seen in 
ADPKD and that it modifies the ADPKD phenotype. The specific aim was to: 
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Determine if Cux1 is required to develop renal cysts in a mouse model carrying a kidney 
specific deletion in the Pkd1 gene. 
1. Characterize mice with a kidney specific deletion in the Pkd1 gene (chapter 2). 
2. Characterize Pkd1 mutant mice carrying a targeted mutation in Cux1 (chapter 3). 
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Chapter Two 
Ectopic expression of Cux1 is associated with reduced p27 expression and 
increased apoptosis during late stage cyst progression upon inactivation of Pkd1 in 
collecting ducts  
Binu M. Paul, Dianne Vassmer, Aaron Taylor, Lynn Magenheimer, Carol G. Carlton, Klaus B. 
Piontek, Gregory G. Germino and Gregory B. Vanden Heuvel. 
Abstract 
Polycystic kidney diseases (PKD) are inherited disorders characterized by fluid-filled 
cysts primarily in the kidneys.  We previously reported differences between the expression of 
Cux1, p21 and p27 in the cpk and Pkd1 null mouse models of PKD. Embryonic lethality of Pkd1 
null mice limits its study to early stages of kidney development.  Therefore, we examined mice 
with a collecting duct specific deletion in the Pkd1 gene.  Cux1 was ectopically expressed in the 
cyst lining epithelial cells of newborn, P7 and P15 Pkd1CD mice.  Cux1 expression correlated 
with cell proliferation in early stages of cystogenesis, however, as the disease progressed, fewer 
cyst lining cells showed increased cell proliferation.  Rather, Cux1 expression in late stage 
cystogenesis was associated with increased apoptosis.  Taken together, our results suggest that 
increased Cux1 expression associated with apoptosis is a common feature of late stage cyst 
progression in both the cpk and Pkd1CD mouse models of PKD.  
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Introduction 
The Cux1 transcription factor is involved in the regulation of cell proliferation, 
differentiation and development (119, 133-136). Cux1 is a murine homologue of the Drosophila 
gene Cut. Cut is required for the proper development of malpighian tubules in Drosophila which 
are the insect excretory organs that serve as their primitive kidney (88, 87, 99, 115, 134). 
Cux1 is highly expressed in the developing kidney, with highest expression restricted to 
the nephrogenic zone (88). As development proceeds, the levels of Cux1 decrease with only low 
levels of Cux1 detected in adult kidneys (101). Cux1 regulates the cell cycle by transcriptionally 
repressing the cyclin dependent kinase inhibitors (CKI) p21 and p27 (124, 118).  
  High rates of cell proliferation are one of the striking features of cyst epithelial cells in 
PKD, a life-threatening genetic disease. PKD can be inherited in two different forms:  an 
autosomal recessive form (ARPKD), or an autosomal dominant form (ADPKD), both 
characterized by fluid-filled cysts primarily in the kidneys (2). ADPKD results from mutations in 
either of the two genes, PKD1 or PKD2 (2, 50, 137, 138), while mutations in a single locus, 
PKHD1, are responsible for ARPKD (8).  
Polycystin1, the protein product of PKD1 co-localizes with complexes involved in cell-
to-cell and cell-to-extracellular matrix interactions. These complexes in turn have a regulatory 
role in cell proliferation (139). Polycystin1 also interacts with Polycystin2, the protein product of 
PKD2, to induce p21 (48), a transcriptional target of repression by Cux1 (118).   
Several murine models have been described for PKD. A well characterized murine model 
of PKD is the cpk mouse model. The disease is transmitted in a recessive fashion and it shows a 
striking resemblance to human ARPKD in terms of cyst localization and disease progression (3, 
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140). A targeted mutation in the Pkd1 gene (Pkd1 null) has also been described.  The Pkd1 null 
mice which are homozygous for this mutation present with kidney cysts and die embryonically 
(60).  
Cux1 is upregulated in the kidneys of both the cpk and the Pkd1 null mouse models 
(124). Cells from human ADPKD kidneys also show increased expression of Cux1 (87). 
Analysis of cpk and the Pkd1 null mouse models showed a striking difference between the 
expression of Cux1, p21, p27, as well as, cell proliferation and apoptosis. Kidneys from Pkd1 
null embryos showed increased expression of Cux1. However, in the kidneys of cpk mice, Cux1 
upregulation was not observed until late stages of cystogenesis. While p21 was not detected in 
embryonic kidneys from Pkd1 null mice, Cux1 and p21 were co-expressed in cyst lining cells in 
cpk mice.  In contrast to the reduced expression of p27 in kidneys from Pkd1 null embryos, we 
saw an increase in p27 expression in the cpk kidneys during late stages of cystogenesis. 
Apoptosis was also increased in the cpk kidneys during late stages of cystogenesis (124). 
These results suggested a model in which cystogenesis proceeds through different 
mechanisms in the Pkd1 null mice and cpk mice. However, since the Pkd1 null mice died 
embryonically, our analysis of cystogenesis in that mouse model was restricted to the earliest 
stages of cystogenesis. In order to analyze the role of Cux1 in ADPKD beyond the embryonic 
stages of cystogenesis, we examined a mouse model with a collecting duct specific deletion of 
the Pkd1 gene. Early stages of cystogenesis in this mouse model showed an increase in Cux1 
expression that correlated with increased cell proliferation. In more advanced stages of 
cystogenesis, the increased expression of Cux1 was associated with an increase in apoptosis.  
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Experimental Procedures 
Pkd1cond mice 
The Pkd1cond mouse line has been described previously. This mouse line has loxP sites 
flanking exons 2 through 4 of the murine Pkd1 gene, thereby allowing the inactivation of the 
gene specifically in the tissue of interest. The Pkd1cond allele is fully functional and mice 
homozygous for this allele are viable and healthy (147). 
Hoxb7/Cre mice 
The Hoxb7/Cre transgenic mouse line (STOCK Tg(Hoxb7-cre)13Amc/J) was purchased 
from Jackson Laboratory (Bar Harbor, ME) and the stock colonies are maintained at the 
University of Kansas Medical Center. The Cre recombinase in this transgenic mouse is expressed 
under the control of the mouse Hoxb7 enhancer and promoter. The expression of Hoxb7/ Cre can 
be detected in the mesonephric duct of the kidney as early as embryonic day 9.5. Thereafter, Cre 
expression can be seen in the mesonephric duct derivatives of the kidney, which include the 
collecting duct and the ureteral epithelia (148).  
Breeding strategy 
We crossed mice heterozygous for the Pkd1cond allele to Hoxb7/Cre+ mice. Brother-sister 
matings were set up between F1 progeny having the Pkd1cond/wt; Hoxb7/Cre+ genotype. A total of 
59 out of 266 pups were Pkd1CD (homozygous for the Pkd1cond allele and heterozygous for the 
Hoxb7/cre transgene). All protocols were approved by the University of Kansas Medical Center 
Animal Care and Use Committee. The University of Kansas Medical Center is fully accredited 
by the American Association of the Accreditation of Laboratory Animal Care.  
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Characterization of cystic phenotype 
We analyzed the offspring of F1 crosses at postnatal day 0 (P0, newborn), P7, and P15 
stages. Kidneys were harvested from newborn (P0), 7-day old (P7), 12-day old (P12) and 15-day 
old (P15) mice. Kidneys were weighed and the total kidney weight (KW) was measured as a 
percentage of body weight (BW) for each mouse. Harvested kidneys were fixed in 4% 
paraformaldehyde and embedded in paraffin. Mid-sagittal sections (5µm) of cystic kidneys, 
stained with Haematoxylin and eosin (H & E), were utilized to stage the cysts, as described 
previously (87). Cysts with up to 50 cyst-lining epithelial cells were defined as small, medium if 
there were 51-200 cyst-lining epithelial cells, and advanced (large) stage cysts if there were more 
than 200 cyst lining epithelial cells. The cystic index (ratio of cystic area in the kidney to the 
total kidney area) was measured in H & E stained cystic kidney sections using ImageJ (NIH) 
software. 
Serum chemistry 
Blood was collected by exsanguination, following decapitation and immediately 
centrifuged at 2000 g to collect serum. Blood urea nitrogen (BUN) in these samples was 
measured using QuantiChromTM Urea Assay Kit (BioAssay Systems, Hayward, CA). 
Immunofluorescence (IF) 
Immunofluorescence was performed as previously described (124). Kidney sections were 
incubated with 1M ammonium chloride to quench autofluorescence, washed in PBST, and 
blocked in 10% normal goat serum (NGS) or 10% normal horse serum (NHS) for 1 hour at room 
temperature. Rabbit anti-Cux1 (1:50, Santa Cruz), mouse anti-PCNA (1:3000, Sigma), mouse 
anti-p21 (1:100, AbCam), primary antibody was applied to sections and incubated for 1 hour at 
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room temperature. Bound anti-Cux1 antibodies were detected using biotinylated goat anti-rabbit 
(1:400) secondary antibody (Vector) followed by FITC-avidin (5µg/ml, Vector). PCNA and p21 
antibodies were detected using horse anti-mouse Texas red or FITC-conjugated secondary 
antibody (Vector, 1:400). To identify collecting ducts, kidney sections were incubated with 
biotinylated dolichos biflorus agglutinin (20ug/ml DBA, Vector) for 1 hour at room temperature, 
followed by incubation with FITC-conjugated avidin. Sections were then washed in PBST, 
mounted with Vectashield medium with DAPI (Vector) and images were captured with an 
Optronics Magnafire digital camera.  
Western blot analysis 
Whole tissue lysates were prepared from frozen kidneys. Protein (40ug) was loaded onto 
4-15% or 12% SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked 
in 5% milk in PBST. Membranes were probed with anti-p27 antibody (1:100, AbCam), or anti-β-
tubulin antibody (1:1000, Sigma), followed by PBST washes and HRP-peroxidase secondary 
antibody (1:10,000) application.   
TUNEL assay 
Sections were processed for Terminal deoxynucleotidal transferase (TdT)-mediated 
dUTP-nick-end labeling (TUNEL) with the TUNEL Apoptosis Detection Kit (Upstate) 
according to manufacturer's instructions. Sections were counterstained with DAPI, cover-
slipped, and visualized on a fluorescence microscope. Images were captured with an Optronics 
Magnafire digital camera. 
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Statistics 
Two-tailed t-tests were performed in all statistical studies.  
Results 
Our previous studies with cpk and Pkd1 null mice suggested different mechanisms of 
PKD progression in these mouse models. These studies showed that increased expression of 
Cux1 was primarily associated with cell proliferation in the Pkd1 null mice. In contrast, 
increased expression of Cux1 in the cpk mice during late stages of cyst progression was 
associated with apoptosis (124).   
Embryonic lethality of Pkd1 null mice limited our studies to the early stages of 
cystogenesis. Therefore, in the present study, we have examined an ADPKD mouse model with a 
conditional deletion of the Pkd1 gene in the kidneys. We crossed the Pkd1cond mice with 
Hoxb7/Cre mice to generate a kidney specific deletion of the Pkd1 gene. Hoxb7/Cre is active in 
the mesonephric duct of the kidney as early as embryonic day 9.5 and its expression continues in 
the mesonephric duct derivatives of the kidney, which include collecting ducts and ureteral 
epithelia (148). Mice in which the Pkd1 gene was disrupted using Hoxb7/cre were designated 
Pkd1CD (Pkd1collecting duct) mice.  
Morphological evaluation of the Pkd1CD mice 
We analyzed Pkd1CD mice at various ages, beginning at postnatal day 0 (P0). Mice with 
Hoxb7/Cre+/Pkd1cond/wt or Hoxb7/Cre+/Pkd1wt/wt genotypes were used as controls. Morphological 
analysis of kidney sections from newborn Pkd1CD mice revealed microscopic cysts. These 
microscopic dilations were derived from both cortical and medullary collecting ducts (Figure 2-
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1A). In mice, nephrogenesis continues until about postnatal day 7 (P7) (28). Therefore, we 
analyzed Pkd1CD mice at this time point. By P7, Pkd1CD mice had a slight bulging of their flanks, 
which was visible only upon careful examination. The kidneys of these mice were larger and 
cystic compared to their age-matched control littermates (Figure 2-1B). The kidneys also had 
more and larger cysts, with less normal parenchyma, compared to cystic kidneys isolated from 
newborn Pkd1CD mice (Figure 2-1E-F). By P15, Pkd1CD mice presented with huge bilateral 
masses on their flanks. The kidneys of these mice were larger and grossly cystic in comparison 
to age-matched control littermates, or when compared to Pkd1CD mice at P0 and P7 (Figure 2-
1D). The kidneys were crowded by cystic tissue and very little normal renal parenchyma was 
preserved (Figure 2-1G-H).   
 
 
 
 
Figure 2-1 Morphological evaluation of the Pkd1CD mice. A and B: Bright field images of 
newborn kidneys from a Pkd1CD (B) mouse and an age-matched control littermate (A) 
Microscopic cyst dilations (arrows) can be seen in the Pkd1CD kidney. Scale bar= 500μm. C and 
D: Gross appearance of littermate kidneys (control and Pkd1CD) at P7 (C) and P15 (D) 
respectively. The Pkd1CD kidneys are large and severely cystic compared to the controls. 
Pkd1CD kidney at P15 is also larger compared to the Pkd1CD kidney at P7. E-H: H & E stained 
kidney sections from control and Pkd1CD mice at P7  (E-F)and P15 (G-H) respectively. By P15, 
the Pkd1CD kidneys lost most of the normal renal parenchyma and the kidneys were crowded 
with cystic tissue. Scale bar= 100μm. 
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Since HoxB7/Cre specifically deletes the Pkd1 gene in the ureteric bud derivatives of the 
kidney, we expected all the cysts in the Pkd1CD mice to have originated from the collecting 
ducts. Labeling of kidney sections from newborn, P7 and P15 Pkd1CD mice with Dolichus 
Biflorus Agglutinin (DBA), confirmed the collecting duct origin of the cysts (Figure 2-2 A-F).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-2: All the cysts in the Pkd1CD kidneys originated from collecting ducts. Kidney 
sections from Pkd1CD mice were labeled with DBA (green, A, C and E) and merged with 
DAPI staining (blue, B, D and F). Arrows show some collecting duct derived cysts labeled 
with DBA. Arrowheads show normal collecting ducts labeled with DBA. A, B: Kidney 
sections from a newborn Pkd1CD mouse. C, D: Cystic kidney from a Pkd1CD mouse at P7. E, 
F: Cystic kidneys from a Pkd1CD mouse at P15. Scale bar= 100μm.
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Analysis of PKD severity in the Pkd1CD mice 
To evaluate disease progression in Pkd1CD mice, we determined the ratio of kidney 
weight to body weight (KW/BW) at P7 and at P15 (Figure 2-3A). Kidneys harvested from 
Pkd1CD mice were significantly larger compared with kidneys from control mice, both at P7 and 
P15. To further analyze the Pkd1CD cystic phenotype, isolated cystic kidneys were examined 
morphologically. Histological analysis showed that the cystic index (the percentage of cystic 
area) increased between P7 and P15 (Figure 2-3B). The developmental stage of the renal cysts in 
Pkd1CD mice was determined by counting the number of cells lining the cysts (see experimental 
procedures). The results showed that cystic kidneys in P7 mice were mainly composed of small 
and medium cysts, while advanced stage cysts were also seen in the cystic kidneys of P15 mice 
(Figure 2- 3C). Cystic kidney disease is directly correlated with reduced renal function and high 
BUN levels. Accordingly, Pkd1CD mice at P7 and P15 showed higher BUN values compared to 
controls, indicative of decreased renal function (Figure 2- 3D). 
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Figure 2-3: Analysis of PKD severity in the Pkd1CD mice. A: KW/BW of P7 and P15 Pkd1CD 
mice compared to their respective age-matched controls. KW/BW was significantly increased in 
P7 (p value <0.0001) and P15 (p value 0.03) Pkd1CD mice compared to their age-matched 
controls. B: Cystic index of kidneys from Pkd1CD mice at P7 and P15 are shown. Cystic index 
was significantly higher in P15 kidneys compared to P7 kidneys from Pkd1CD mice (p value 
0.02). C: Cysts classified according to their developmental stages are shown. Small cysts had up 
to 50 cyst-lining epithelial cells. Cysts which had 51-200 cyst-lining epithelial cells were 
defined as medium cysts. Advanced stage or large cysts were lined with more than 200 cyst-
linging epithelial cells. By P7, Pkd1CD kidneys were comprised mainly of small cysts. Medium 
cysts were also seen in these cystic kidneys. However, no advanced cysts were seen in these 
kidneys. The Pkd1CD kidneys at P15 showed more medium cysts and also a small percentage of 
advanced stage cysts. D: BUN values from the Pkd1CD mice were compared with their age-
matched controls. Increased BUN values were observed in Pkd1CD mice at both P7 (p value 
<0.0001) and P15 (p value <0.0001) compared to their respective age matched controls. 
Between P7 and P15, BUN values did not show a great difference.  
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Cux1 is ectopically expressed in the Pkd1CD mice. 
Cux1 is highly expressed during normal kidney development with the highest level of 
expression seen in the nephrogenic zone of the kidney (88, 124).  Since Cux1 is a cell cycle 
regulatory gene and increased cell proliferation is a hallmark characteristic of PKD, we analyzed 
the expression pattern of Cux1 at various stages of cystogenesis in the Pkd1CD mice. As 
expected, high levels of Cux1 were seen in the nephrogenic zone of newborn control kidneys 
(Figure 2-4 A-B), as well as in the Pkd1CD kidneys  (Figure 2-5 A-B). Cux1 was also ectopically 
expressed in the cyst lining epithelium of kidneys from Pkd1CD mice (Figure 2-5A-B). The 
continuation of the proliferative phase of kidney development at P7 correlated with continued 
expression of Cux1 in the kidneys of control mice (Figure 2-4 C-D). Cystic kidneys from P7 
Pkd1CD mice showed increased expression of Cux1, (Figure 2-5 C-D) compared to the controls. 
By P15, control kidneys showed little Cux1 expression (Figure 2-4).  In contrast, cystic kidneys 
from Pkd1CD mice continued to show high and ectopic expression of Cux1 (Figure 2-5 E-F).  
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Figure 2-4: Cux1 expression in the control kidneys. Kidney sections from control mice 
were labeled with Cux1 (green, A, C and E) and merged with DAPI staining (blue, B, D and 
F). A, B: Kidney section from a newborn mouse. Cux1 labeling was seen in the nephrogenic 
zone (*) and tubules (arrows). C, D: Kidney section from a P7 control mouse. Cux1 staining 
in the nephrogenic zone (*) is decreased as compared to the newborn mouse. Cux1 was also 
seen in some tubules (arrows). E, F: Kidney section from a P15 control mouse. Cux1 levels 
are much reduced by P15 compared to the newborn and P7 control kidneys. Arrows point 
toward Cux1 positive nuclei. Scale bar= 50μm. 
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Figure 2-5: Ectopic expression of Cux1 in the Pkd1CD kidneys. Kidney sections from 
Pkd1CD mice were labeled with Cux1 (green, A, C and E) and merged with DAPI 
staining (blue, B, D and F). A, B: Kidney section from a newborn Pkd1CD mouse. Cux1 
labeling was seen in the nephrogenic zone (*) and cysts (arrows). C, D: Cystic kidney 
section from a P7 Pkd1CD mouse. Arrows point toward Cux1 positive nuclei in the cysts. 
Arrowheads show normal tubules positive for Cux1. E, F: Cystic kidney section from a 
P15 Pkd1CD mouse. Arrows point toward Cux1 positive nuclei in the cysts. All the cyst-
lining epithelial cells were Cux1 positive. Scale bar= 50μm. 
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Early and late stage of cystogenesis in the Pkd1CD mice is associated with increased cell 
proliferation and increased Cux1 expression. 
Increased cell proliferation is one of the characteristic features of PKD. We have 
previously shown that increased expression of Cux1 is associated with increased cell 
proliferation in human ADPKD cystic epithelia and in several mouse models of PKD (87, 124). 
We analyzed cell proliferation and its association with Cux1 in the Pkd1CD mice by labeling 
kidney sections for Cux1 and the cell proliferation marker PCNA.  PCNA staining co-localized 
with Cux1 in the nephrogenic zone and in the cyst lining cells of newborn and P7 Pkd1CD mice 
(Figure 2-7). By P15, the nephrogenic zone is essentially gone, however, the cyst lining cells 
expressed PCNA and Cux1 (Figure 2-7 G-I). Kidney sections from control newborn mice 
showed high levels of cell proliferation, which were associated with Cux1 expression. In 
contrast, kidney sections from P7 and P15 control mice showed little PCNA or Cux1 expression 
(Figure 2-6 A-I).  
 
 
 
 
 
 
 
 
  73
 
 
 
 
 
 
 
 
Figure 2-6: Decreased Cux1 expression and cell proliferation in the control kidneys. 
Kidney sections from control mice were co-labeled with Cux1 (green, A, D and G), and 
PCNA (red, B, E and H). A merge between Cux1 and PCNA is also shown (C, F and I). A, B, 
C: Newborn control kidney section. Cux1 and PCNA co-localized in the nephrogenic zone (*). 
Arrows point toward tubules which show no co-localization between Cux1 and PCNA. D, E, 
F: Kidney section from a P7 control mouse. Very few tubules stained positive for PCNA. 
Cux1 and PCNA co-localized in some tubules (arrowheads). Arrows point toward tubules in 
which Cux1 and PCNA did not co-localize. G, H, I: Kidney section from a P15 control mouse. 
Very few tubules stained positive for PCNA. Cux1 and PCNA co-localized in some tubules 
(arrowheads). Arrows point toward tubules in which Cux1 and PCNA did not co-localize. 
Scale bar= 50μm. 
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Figure 2-7: Early and late stage cystogenesis in Pkd1CD mice is associated with 
increased cell proliferation. Kidney sections from Pkd1CD mice were co-labeled with Cux1 
(green, A, D and G), and PCNA (red, B, E and H). A merge between Cux1 and PCNA is 
also shown (C, F and I). A, B, C: Newborn Pkd1CD kidney section. Cux1 and PCNA co-
localized in the nephrogenic zone (*). Arrows point toward nuclei in the cysts which show 
co-localization of Cux1 and PCNA. Arrowheads show normal tubules where Cux1 and 
PCNA did not co-localize. D, E, F: Kidney section from a P7 Pkd1CD mouse. Arrows point 
toward nuclei in the cysts which show co-localization of Cux1 and PCNA. Arrowheads 
show cystic nuclei in Cux1 and PCNA did not co-localize. G, H, I: Kidney section from a 
P15 Pkd1CD mouse. All of the cyst-lining epithelial cells were positive for Cux1. However, 
only some of them showed co-localization with PCNA (arrowheads). Arrows point toward 
the co-localization of Cux1 and PCNA in cyst-lining epithelial cells. Scale bar= 50μm. 
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Late stage of cystogenesis in the Pkd1CD mice is associated with increased apoptosis and 
increased Cux1 expression. 
Apoptosis is another pathological feature seen in PKD (24). We used the TUNEL assay 
to analyze apoptosis in kidney sections from Pkd1CD mice. Kidney sections from newborn 
Pkd1CD mice were mostly TUNEL negative (Figure 2-9A), while kidney sections from P7 and 
P15 Pkd1CD mice showed increased apoptosis (Figure 2-9 B-C). In contrast, age-matched 
littermate controls showed little or no apoptosis (Figure 2-8).  
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Figure 2-8: Decreased apoptosis in the control kidneys. Kidney sections from 
control mice were stained with TUNEL kit (green, A, C and E) to label apoptotic 
nuclei and were merged with DAPI (blue, B, D and F) staining. Very few apoptotic 
nuclei (arrows) were seen in control mice. A, B: Newborn control kidney section. C, 
D: Kidney section from a P7 control mouse. E, F: Kidney section from a P15 control 
mouse. Scale bar= 50μm. 
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Figure 2-9: Late stage cystogenesis in the Pkd1CD mice is associated with increased 
apoptosis. The terminal deoxynucleotidal transferase (TdT)-mediated deoxyuridine 
triphosphate (dUTP) nick-end labeling (TUNEL) method was used to identify apoptotic 
cells in newborn (A), P7 (B) and P15 (C) kidneys from Pkd1CD mice.  A: Newborn 
Pkd1CD kidney section. Very few apoptotic nuclei (arrows) were seen in the newborn 
kidneys. B: Kidney section from a P7 Pkd1CD mouse showing cyst-lining epithelial cells 
positive for TUNEL labeling (arrows). C: Kidney section from a P15 Pkd1CD mouse 
showing cyst-lining epithelial cells that are TUNEL positive (arrows). Scale bar= 50μm. 
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Increased expression of Cux1 correlates with the down regulation of p27 in the Pkd1CD mice. 
Since p27 and p21 are targets of transcriptional repression by Cux1, we analyzed the 
levels of these proteins in total kidney lysates from the Pkd1CD mice. Compared to controls, p27 
levels were reduced in the kidneys from both P7 and P15 Pkd1CD mice (Fig 2-10 A). p21 is 
normally downregulated very early during kidney development. Accordingly, we were unable to 
detect p21 expression in the Pkd1CD mice (data not shown).  
 
 
 
 
 
 
 
Discussion 
Polycystic kidney disease is a systemic disorder characterized by fluid-filled renal cysts 
together with several extra-renal features. Autosomal dominant polycystic kidney disease 
(ADPKD) results from mutations in one of two genes: PKD1, which encodes the polycystin-1 
protein, and PKD2, which encodes the polycystin-2 protein. Increasing evidence suggests that 
PKD is a developmental disorder (60, 141). Aberrant cell proliferation is a pathological feature 
of PKD and micropolyps or foci of proliferating cells can be found populating the kidneys of 
Figure 2-10 Downregulation of p27 in the Pkd1CD mice. A: Total kidney lysates were 
prepared from P7 and P15 Pkd1CD mice and their respective age matched controls. A 
western blot analysis was done on these lysates using antibodies raised against p27 and 
β-tubulin (loading control). A loss of p27 protein expression was seen in the Pkd1CD 
mice.  
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human PKD patients and experimental animal models of PKD (87, 142-144). The role of 
polycystins in regulating the cell cycle has been described in which polycystin 1, in cooperation 
with polycystin 2, functions to regulate the cyclin kinase inhibitor p21 by signaling through the 
JAK-STAT pathway (48). 
Cux1 is a homeobox gene that regulates the cell cycle by transcriptionally repressing the 
cyclin kinase inhibitors p21 (118) and p27 (104, 124). In the developing kidney, Cux1 is highly 
expressed in the nephrogenic zone, an area of high cell proliferation, where it functions to 
repress p27, thereby keeping cells in the cell cycle. As nephrons mature, the levels of Cux1 
decrease, and cells move out of the cell cycle and terminally differentiate. Our previous studies 
showed the ectopic expression of Cux1 in the Pkd1 null and cpk mouse models of polycystic 
kidney disease (124), and in cells obtained from the renal cysts of ADPKD patients (87). 
Comparative studies of the expression of Cux1 and its correlation with cyst progression were 
done in the Pkd1 null and cpk mouse models. Kidneys from the Pkd1 null mice showed 
increased expression of Cux1, which correlated with increased cell proliferation. In contrast, 
increased expression of Cux1 during late stages of cyst progression in the cpk mice was 
associated with apoptosis. These studies suggested a difference in the mechanism of cyst 
progression between these animal models. However, the embryonic lethality of Pkd1 null mice 
limited our studies to the embryonic stages of cystogenesis. Analysis of the Pkd1CD mice has 
allowed us to examine cyst progression in a postnatal ADPKD mouse model.  
Microscopic cysts derived from both cortical and medullary collecting ducts were 
observed in the kidneys from newborn Pkd1CD mice. Even though the deletion of the Pkd1 gene 
was restricted to the collecting ducts, Pkd1CD mice developed severe PKD as early as P7 where 
the entire kidney was crowded by cystic tissue, and ectopic expression of Cux1 was seen in the 
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kidneys of newborn and P7 Pkd1CD mice, where it was associated with cell proliferation. Cux1 
was widely expressed in the cyst lining cells from P15 Pkd1CD kidneys, however, it did not 
colocalize with PCNA in many of the cyst lining cells. This apparent uncoupling of Cux1 
expression and cell proliferation is similar to what was previously seen in the cpk mice. 
However, the kidneys of cpk mice did not show increased expression of Cux1 until late stages of 
cystogenesis. 
Consistent with the increased expression of Cux1, we saw downregulation of p27 in the 
Pkd1CD kidneys, similar to what we previously reported for the Pkd1 null mouse. This also 
contrasts the previously reported upregulation of p21 and p27 in cystic kidneys from cpk mice.  
Apoptosis is associated with several mouse models of cystic disease (145). While cystic 
kidneys from newborn Pkd1CD mice did not show higher levels of apoptosis than controls, there 
was an increase in apoptosis as the disease progressed, similar to our observations in the cpk 
mouse model. In the cpk mice, there was co-localization of p21 and Cux1 that was associated 
with increased apoptosis, suggesting contradictory signals to proliferate or arrest (124). 
However, we did not see ectopic expression of p21 in the Pkd1CD mice. While conditional 
deletion of Pkd1 using Ksp Cre did not show significant changes in apoptosis (146), we did see 
some TUNEL labeling at very advanced stages of cyst growth, although it seemed to be 
restricted to only a small subset of large cysts. Thus, although there appears to be apoptosis in 
the very large cysts, it is probably not involved in the cystogenic process, but in the loss of 
already damaged cells.   
Taken together, our studies support our previous conclusion that differences exist in the 
mechanism of cyst progression in the Pkd1CD and cpk mouse models of PKD. The association 
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between the expression of Cux1 and cell proliferation is well established. However, the 
association between Cux1 and apoptosis remains to be elucidated. 
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Chapter Three 
Cux1 is required for polycystic kidney disease progression in an ADPKD mouse 
model 
Binu M. Paul, Lynn Magenheimer, Carol G. Carlton and Gregory B. Vanden Heuvel 
Abstract 
Autosomal Dominant Polycystic Kidney Disease (ADPKD) is one of the most common 
monogenic hereditary disorders in humans characterized by fluid-filled cysts, primarily in the 
kidneys. We previously reported an ADPKD mouse model with a collecting duct specific 
deletion in the Pkd1 gene (Pkd1CD). These mice developed severe PKD by postnatal day 7 (P7) 
and died between P15 and P21. Cux1, a cell cycle regulatory gene, important during kidney 
development, was ectopically expressed in the cyst-lining cells of the Pkd1CD mice. The 
expression pattern of Cux1 also correlated with the downregulation of its transcriptional 
repression targets, p21 and p27. Our results using the Cux1 transgenic mouse showed that the 
overexpression of Cux1 by itself is insufficient to develop PKD. Here we report a double mutant 
mouse model which has a conditional deletion of the Pkd1 gene in the renal collecting ducts 
together with a targeted mutation in the Cux1 gene (Pkd1CD/Cux1ΔHD). Compared to the 
Pkd1CD mice, the Pkd1CD/Cux1ΔHD+/- mice presented with a reduction in the severity of PKD 
and also had a longer life span. The delay in the development of PKD in these double mutant 
mice can be explained by the reduced gene dosage of Cux1 with a concomitant expression of its 
transcriptional repression target, p27.  
 
  83
Introduction 
Polycystic Kidney Disease (PKD) is grouped under a set of nephropathies which often 
progresses to end-stage renal disease (3). It is characterized by the accumulation of fluid-filled 
renal cysts as well as cysts in some other epithelial organs. Cysts can be defined as fluid-filled 
structures that are lined with polarized epithelium (144). Renal cysts arise from the epithelia of 
nephrons and the renal collecting system. The single layer of cells which line the cysts show 
higher rates of cellular proliferation (2).  
PKD is inherited in two different forms, as an autosomal recessive form (ARPKD), or as 
an autosomal dominant form (ADPKD) (2). ADPKD is a systemic disorder that can have an 
adult as well as in utero onset (12). ADPKD is genetically heterozygous. Mutations in either of 
two genes, PKD1 or PKD2, can cause ADPKD. Protein products of the PKD1 (polycystin-1) and 
PKD2 (polycystin-2) genes are collectively known as polycystins (2).  
Polycystins regulate the cell cycle by activating the cyclin dependent kinase inhibitor 
(CKI) p21, signaling through the JAK-STAT and Id2 pathways (48-49). The CKI, p21, is also a 
transcriptional repression target of Cux1 (118), a cell cycle regulatory gene important during 
kidney development.  
Cux1 is the murine homologue of the Cut gene in Drosophila melanogaster. Other 
mammalian homologues of Drosophila Cut include CCAAT displacement protein/ CDP/ CUX1 
(human), Clox (dog), and CDP2 (rat) (97, 99). In Drosophila, Cut is required for the proper 
development of the insect excretory organ, Malpighian tubules. Malpighian tubules serve as the 
primitive kidneys in these organisms. In murine kidneys, Cux1 is highly expressed during 
development and the highest expression is found in the nephrogenic zone which has actively 
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proliferating cells (88). Cux1 is down-regulated as development ceases and only low levels of 
Cux1 are found in adult kidneys (101).  
There are five evolutionarily conserved domains in the Cut proteins. These include a 
region that forms a coiled-coil structure, three Cut repeats, and the Cut homeodomain (HD) (98).  
The Cut repeats, called CR1, CR2 and CR3, each contain approximately 70 amino acids, and 
along with the homeodomain, are each capable of binding DNA (98, 149). Cux1 functions as a 
cell cycle dependent transcriptional repressor by negatively regulating the expression of the 
above-mentioned CKI, p21, and also of another CKI, p27 (101). 
Consistent with the transcriptional repression activity of Cux1 on p27, a mouse model 
which lacks p27, has a similar phenotype as the Cux1 transgenic mouse. Both the Cux1 
transgenic and the p27 knockout mice present with multiorgan hyperplasia including renal 
hyperplasia (101, 126, 150-151). In contrast, p21 knockout mice do not show any kidney 
hyperplasia (127). 
Sinclair et al reported the cux/CDPΔHD/ΔHD mutant mouse model which has a deletion in 
the C-terminal domain of the Cux1 protein (122). This deletion generates a mutant Cux1 protein 
which has a loss of its homeodomain, repression domain and nuclear localization signal (NLS). 
The mutant Cux1 protein is excluded from the nucleus and is sequesterdt in the cytoplasm from 
the loss of its NLS. Hence homozygous cux/CDPΔHD/ΔHD mutants have a functional loss of Cux1 
(122-123).  
The role of Cux1 in PKD has been established previously. Cux1 is ectopically expressed 
in the cyst epithelium of different mouse models of PKD, but is expressed in only very low 
levels in phenotypically normal littermates (88, 124). In addition, Cux1 is ectopically expressed 
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in human ADPKD cells (87). Cux1 transgenic mice which overexpress Cux1 under the control of 
a CMV promoter, develop multiorgan hyperplasia including kidney hyperplasia, but do not 
develop PKD (101). These results suggest that the overexpression of Cux1 is insufficient to 
develop PKD in mice.  
To test the hypothesis that Cux1 is required to develop PKD, we generated a conditional 
Pkd1 deletion mouse line (Pkd1CD) that also carries a targeted deletion in the Cux1 gene 
(Pkd1CD/Cux1ΔHD).  While the Pkd1CD mice developed severe PKD by postnatal day 7 (P7) 
(152), mice which were Pkd1 homozygous null and heterozygous for Cux1ΔHD 
(Pkd1CD/Cux1ΔHD+/-) were healthy and had fewer renal cysts even at 3 weeks of age. Whereas 
most of the Pkd1CD mice died within 2-3 weeks of age, the Pkd1CD/Cux1ΔHD+/-mice had a 
longer life span and lived for about 4 weeks of age. The cyclin kinase inhibitor p27, which is a 
transcriptional repression target of Cux1, was up-regulated specifically in the collecting ducts of 
the double mutant mice where Pkd1 had been deleted.  Moreover, this was associated with a 
marked decrease in cell proliferation. Reduced gene dosage of Cux1 together with the resultant 
re-expression of p27 may explain the reduced cystic severity as well as the longer life span in 
these double mutant mice.  
Our previous results show a reduction in nuclear cathepsin-L, a protease that cleaves the 
full length form of Cux1 in ADPKD and Pkd1 null kidneys (87). This in turn leads to the 
accumulation of the full length Cux1 and increased cell proliferation. Because 
Pkd1CD/Cux1ΔHD heterozygous mice retain a normal Cux1 allele, the reduced cathepsin-L 
likely results in the accumulation of full length Cux1 and subsequent progression of PKD in 
these animals. Taken together, our results suggest that Cux1 gene dosage influences the 
progression of cystic disease in an ADPKD mouse model. 
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Experimental procedures 
Animals  
All animal protocols were approved by the University of Kansas Medical Center Animal 
Care and Use Committee. The University of Kansas Medical Center is fully accredited by the 
American Association of the Accreditation of Laboratory Animal Care.  
Pkd1CD mice 
The Pkd1CD mouse line has been described previously (152). To generate this mouse line, 
heterozygous Pkd1cond mice were crossed with Hoxb7/Cre mice.  Hoxb7/ Cre is expressed in the 
mesonephric duct of the kidney as early as embryonic day 9.5 and thereafter, in the mesonephric 
duct derivatives of the kidney, which include the collecting duct and the ureteral epithelia (148). 
The Pkd1cond mouse line has loxP sites flanking exons 2 through 4 of the murine Pkd1 gene 
(147). A cross between the Pkd1cond and Hoxb7/Cre mice yield the Pkd1CD mice which have a 
conditional deletion of the Pkd1 gene in their renal collecting ducts. These mice developed 
severe PKD by postnatal day 7 (P7) and died between P15 and P21 (152).  
cux/CDPΔHD/ΔHD mice  
This mouse model has been described previously (122). These mice were generated using 
a homologous gene targeting method in mice which resulted in a deletion of the C-terminal 
domain of the Cux1 protein, a loss encompassing its homeodomain and repression domain. This 
deletion leads to the loss of nuclear localization of Cux1 and the mutant protein is localized in 
the cytoplasm (123). Mice homozygous for the cux/CDPΔHD/ΔHD mutation displayed stunted 
growth, wavy whiskers and cachexia due to muscle wasting. They also had difficulty thriving 
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and gained little weight. Heterozygous cux/CDPΔHD/ΔHD mice are indistinguishable from the wild 
type mice. The cux/CDPΔHD/ΔHD mice will be referred as Cux1ΔHD hereafter.  
Pkd1CD/ Cux1ΔHD mice 
This mouse line was generated by first breeding the heterozygous Pkd1cond mice with the 
Cux1 ΔHD heterozygous mice. The F1 littermates from this cross, which were heterozygous for 
both the Pkd1cond and Cux1ΔHD genes, were crossed onto the Hoxb7/Cre mouse line. Another 
brother-sister cross was set up between the F1 generation of the latter cross to generate Pkd1CD/ 
Cux1ΔHD+/- and Pkd1CD/ Cux1ΔHD-/-mice. 
Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J (mTmG) mice 
The mTmG mice have a TomatoGFP cassette inserted into the Rosa26 locus. The Tomato 
cassette (mT) is flanked by two loxP sites and followed by a polyadenylation signal. The GFP 
cassette (mG) is present after the second loxP site. A chicken actin promoter (pCA) drives the 
constitutive expression of the Tomato cassette in these mice resulting in the presence of red 
fluorescence in all tissues. In the presence of a tissue-specific Cre recombinase, the Tomato 
cassette is deleted and GFP is expressed. This double fluorescent reporter system can therefore 
be used for tracking the activity of the Cre mouse line by following a change in red-to-green 
fluorescence (153).   
Characterization of cystic phenotype 
We analyzed Pkd1CD and Pkd1CD/ Cux1ΔHD mice at postnatal day 0 (P0, newborn), P15 
and P23 stages. Newborn mice were decapitated. Mice at P15 and P23 were anesthetized using 
isoflurane and cervical dislocation was done. Kidneys were harvested from all mice. Harvested 
kidneys were fixed in 4% paraformaldehyde and embedded in paraffin. Mid-sagittal sections 
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(5µm) of cystic kidneys, stained with Haematoxylin and eosin (H & E), were utilized to stage the 
cysts as described previously (87, 154). Epithelial cells lining each cyst were counted. Cysts with 
50 cyst-lining epithelial cells were defined as small cysts and 51-200 cyst-lining epithelial cells 
as medium cysts. Large cysts were defined as having more than 200 cyst lining epithelial cells. 
The cystic index (ratio of cystic area in the kidney to the total kidney area) was measured in H & 
E stained cystic kidney sections using ImageJ (NIH) software. 
Immunofluorescence (IF) 
Kidney sections were treated with 1M ammonium chloride to quench autofluorescence. 
Sections were washed in PBST and blocked in 10% normal goat serum (NGS) or 10% normal 
horse serum (NHS) for 1 hour at room temperature. Sections were treated with rabbit anti-Cux1 
(1:50, Santa Cruz), mouse anti-PCNA (1:3000, Sigma), rabbit anti-p27 (1:100, AbCam) primary 
antibodies for overnight at 40C. Biotinylated goat anti-rabbit (1:400) secondary antibody was 
used to detect Cux1 and p27. The sections were then subsequently incubated with FITC-avidin 
(5µg/ml, Vector). PCNA antibody was detected using a horse anti-mouse Texas Red antibody 
(Vector, 1:400). To identify collecting ducts, kidney sections were labeled either with Pan-
cytokeratin (1:400, Sigma) or dolichus biflorus agglutinin (DBA). Sections were washed in 
PBST after the antibody treatments, mounted with Vectashield medium with DAPI (Vector) and 
images were captured with an Optronics Magnafire digital camera.  
Western blotting 
Whole tissue lysates were prepared from frozen kidneys. Protein (50ug) was loaded onto 
4-15% SDS-PAGE gels and transferred to PVDF membranes. Membranes were blocked in 5% 
milk in PBST. After blocking, membranes were probed with rabbit anti-Cux1 (1:50, Santa Cruz), 
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mouse anti-p27 (1:200, AbCam), or mouse anti-β-tubulin (1:5000, Sigma) primary antibody 
followed by PBST washes and HRP-peroxidase secondary antibody (1:10,000) application.   
TUNEL assay 
Sections were processed for Terminal deoxynucleotidal transferase (TdT)-mediated 
dUTP-nick-end labeling (TUNEL) with the TUNEL apoptosis detection kit (Upstate 
biotechnology) according to manufacturer's instructions. TUNEL- labeled sections were 
counterstained with DAPI, cover-slipped, and visualized on a fluorescence microscope. Images 
were captured with an Optronics Magnafire digital camera. 
Statistics 
Two-tailed t- tests were performed in all statistical studies.  
Results 
We have previously reported the increased expression of Cux1, a cell cycle regulatory 
gene, in different PKD mouse models, as well as in humans with ADPKD (87, 124). The Cux1 
transgenic mouse which overexpresses Cux1, presented with multiorgan hyperplasia including 
kidney hyperplasia, however, these mice did not develop PKD (101). These results led us to 
conclude that the overexpression of Cux1 by itself is insufficient to develop PKD. In order to test 
the hypothesis that Cux1 is required to develop PKD, we generated the Pkd1CD/Cux1ΔHD 
mouse model. These mice have a deletion of the Pkd1 gene in the collecting ducts of their 
kidneys together with a targeted deletion in the Cux1 gene.  
The loss of the NLS of mutant Cux1ΔHD protein and its presentation in the cytoplasm 
has been described previously in mouse embryonic fibroblasts (123). Here we show the 
  90
exclusion of Cux1ΔHD from the nuclei in Cux1ΔHD-/- mouse kidneys. Compared to the nuclear 
localization of Cux1 in the wild type kidneys (Figure 3 A-B), the mutant protein is restricted to 
the cytoplasm in Cux1ΔHD homozygous null kidneys (Figure 3 C-D).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3-1 Loss of NLS leads to the exclusion of mutant Cux1ΔHD protein from 
the nucleus. Kidney sections from wild type and Cux1ΔHD homozygous mice were 
stained with Cux1 antibody. A and B: Cux1 localizes to the nucleus in wild type 
kidneys. C and D: Due to the loss of its NLS, Cux1ΔHD mutant protein is 
sequestered outside the nucleus. Cux1 staining can be seen in the cytoplasm.  
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Cystic dilations are fewer or absent in newborn Pkd1CD/ Cux1ΔHD-/- kidneys  
Newborn Pkd1CD/Cux1ΔHD-/- mice showed none or very few cystic dilations in their 
kidneys compared to newborn Pkd1CD kidneys (Figure 3-2 A and D). We confirmed Hoxb7/Cre 
activity in both the Pkd1CD and Pkd1CD/Cux1ΔHD mice by crossing them with the membrane-
targeted Tomato/Green Fluorescent Protein (mT/mG) double fluorescent reporter mouse strain 
(Gt(ROSA)26Sortm4(ACTB-tdTomato,-EGFP)Luo/J, Jackson Laboratories, Bar Harbor, ME). These 
reporter mice have Tomato and GFP cassettes inserted into their Rosa26 locus. Before Cre 
recombination, a chicken actin promoter drives the constitutive expression of the membrane 
tagged Tomato protein (153). Tissue specific Cre recombination leads to the deletion of the 
Tomato cassette and the expression of GFP in the tissue of interest leading to a change from red-
to green fluorescence. Since we used the Hoxb7/Cre recombinase, which is active in the ureteric 
bud derivatives of the kidney, normal and cystic collecting ducts in these mice expressed GFP 
after Cre recombination, while all the other cells expressed the red Tomato protein (Figure 3- 2 
B-C and E-F).  
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Morphological evaluation of the Pkd1CD/ Cux1ΔHD mice 
Since the Cux1ΔHD homozygous mice had a short life span and died within a week of 
age, we focused our studies mainly on the Pkd1CD/Cux1ΔHD+/- mice.  
When we analyzed Pkd1CD/Cux1ΔHD+/- mice at postnatal day 23, these mice appeared 
healthy and did not show any signs of PKD, such as enlarged flanks, as we had observed in the 
Pkd1CD mice even at P7. The gross appearance of the Pkd1CD/Cux1ΔHD+/- kidneys revealed the 
presence of cysts. However, it was clear from superficial analysis that these kidneys had less 
Figure 3-2 Loss of functional Cux1 in Pkd1CD/Cux1ΔHD homozygous mice results in the 
absence or reduction of renal cysts. A:  Bright field image of a newborn kidney from a Pkd1CD 
mouse. Microscopic cyst dilations (arrows) can be seen in this kidney. D: Bright field image of a 
newborn kidney from a Pkd1CD/Cux1ΔHD-/- mouse. Very few and comparatively small cystic 
dilations were seen in these kidneys (arrows). B-C and E-F: A merge of Tomato (red) and EGFP 
fluorescence is shown in the kidneys from mTmG/ Pkd1CD (B-C) and mTmG/Pkd1CD 
Cux1ΔHD-/- (E-F) mice. Cysts (in B and C) and collecting ducts show a change in red-to-green 
fluorescence while all the other structures continue to show red fluorescence.  A and D, scale 
bar= 200µm. B-C and E-F, scale bar=100 µm.  
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cystic fluid and more normal renal parenchyma compared to the Pkd1CD kidneys at P15 (Figure 
3-3 A-B). Morphological analysis of the Pkd1CD/Cux1ΔHD+/- kidneys at P23 showed the 
presence of cystic dilations (Figure 3-3 F). Compared to the non-cystic kidneys from age-
matched control mice, Pkd1CD/Cux1ΔHD+/- mice were slightly larger (Figure 3-3 B and E). 
Kidneys from Pkd1CD mice were crowded with cystic tissue by P15 (Figure 3-3 D). In contrast, 
Pkd1CD/Cux1ΔHD+/- kidneys at P23 presented with less cystic tissue and more normal renal 
parenchyma (Figure 3-3 F).  
Renal cysts in P23 Pkd1CD/Cux1ΔHD+/- mice were classified according to their 
developmental stages and were compared to the renal cysts from P15 Pkd1CD mice (refer 
experimental procedures). Cystic kidneys in P23 Pkd1CD/Cux1ΔHD+/- mice were mainly 
composed of small and medium sized cysts. Very fewlarge stage cysts were also seen in these 
kidneys. In comparison to the Pkd1CD cystic kidneys, Pkd1CD/Cux1ΔHD+/- kidneys showed an 
increase in the number of small cysts. Medium and large cysts were fewer in the 
Pkd1CD/Cux1ΔHD+/- kidneys compared to the Pkd1CD cystic kidneys (Figure 3-3 G). 
The percentage of cystic area in the Pkd1CD/Cux1ΔHD+/- kidneys was analyzed by 
measuring the cystic index, which is the ratio of cystic area to the total kidney area (Figure 3-3 
H). As observed morphologically, we observed a significant reduction in cystic index in the P23 
Pkd1CD/Cux1ΔHD+/- kidneys compared to that of the P15 Pkd1CD kidneys.   
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Reduced Cux1 gene dosage correlated with the expression of p27 in the Pkd1CD/Cux1ΔHD+/- 
kidneys. 
Ectopic expression of Cux1 was seen in the normal tubules and cystic epithelium of the 
Pkd1CD kidneys. Localization of Cux1 was restricted to the nucleus in these kidneys (Figure 3-4 
A). In contrast, the ectopic expression of Cux1 that was seen in the Pkd1CD/Cux1ΔHD+/- cystic 
kidneys localized to both the nucleus and cytoplasm (Figure 3-4 B).  
Since the CKIs p27 and p21 are transcription repression targets of Cux1, we analyzed the 
expression pattern of these CKIs. We did not see any change in the expression pattern of p21 in 
the Pkd1CD or Pkd1CD/Cux1ΔHD+/- cystic kidneys (data not shown). Kidney sections from 
Pkd1CD and Pkd1CD/Cux1ΔHD+/- mice were co-labeled with p27 and cytokeratin. Cytokeratin 
was used to mark collecting ducts. As previously described (22), a significant reduction in p27 
was seen in the Pkd1CD kidneys by immunofluorescence and western blot analysis (Figure 3-4 C 
and E-F). Cytokeratin positive, collecting duct-derived cysts showed little or no expression of 
Figure 3-3 Morphological evaluation of the Pkd1CD/Cux1ΔHD+/- mice A: Gross 
appearance of severely cystic Pkd1CD kidneys at P15 together with kidneys from age-matched 
non-cystic littermates. B: Gross appearance of a cystic kidney from a Pkd1CD/Cux1ΔHD+/- 
mouse at P23. Control kidneys from age-matched non-cystic littermates are also shown. C 
and D: Bright field images of non-cystic control (C) and Pkd1CD (D) kidneys at P15. E and F: 
Bright field images of non-cystic control (E) and Pkd1CD/Cux1ΔHD+/- (F) kidneys at P23. A, 
scale bar= 2cm. C-F, scale bar=2mm. G: Cysts were classified according to their 
developmental stages. Small cysts had up to 50 cyst-lining epithelial cells. Cysts which had 
51-200 cyst-lining epithelial cells were defined as medium cysts. Large cysts were lined with 
more than 200 cyst-lining epithelial cells. Compared to the Pkd1CD kidneys (n=4), the 
Pkd1CD/Cux1ΔHD+/- (n=2) had more number of small cysts. Intermediate and advanced stage 
cysts were fewer in the Pkd1CD/Cux1ΔHD+/- kidneys compared to the Pkd1CD kidneys. H: 
Cystic index of kidneys from Pkd1CD (n=4) and Pkd1CD/Cux1ΔHD+/- (n=2) mice at P15 and 
P23 are shown. Cystic index was lower in the Pkd1CD/Cux1ΔHD+/- kidneys compared to the 
Pkd1CD kidneys (p value 0.008).  
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p27 in Pkd1CD kidneys (Figure 3-4 C). In contrast, p27 was re-expressed in the cytokeratin 
positive, cyst-lining cells of Pkd1CD/Cux1ΔHD+/- kidneys (Figure 3- 4 D). Western blot analysis 
confirmed the increase in p27 levels in the Pkd1CD/Cux1ΔHD+/- kidneys compared to the Pkd1CD 
kidneys (Figure 3-4 E-F).  
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A decrease in cell proliferation and increase in apoptosis was observed in Pkd1CD/Cux1ΔHD+/- 
kidneys  
Increased apoptosis and cell proliferation are two pathological features in PKD (7, 142, 
144). We analyzed apoptosis by TUNEL assay on Pkd1CD and Pkd1CD/Cux1ΔHD+/- kidney 
sections. As described previously (152), Pkd1CD kidney sections showed an increase in apoptotic 
cells. Most of the cyst-lining cells were TUNEL positive (Figure 3-5 A). TUNEL positive cells 
were also seen in Pkd1CD/Cux1ΔHD+/- kidneys. As in the Pkd1CD kidneys, many of the cyst-
lining cells were apoptotic and TUNEL positive cells were also found in some tubules which 
appeared normal (Figure 3-5 B).  
Cell proliferation was analyzed by staining kidney sections with the cell proliferation 
marker PCNA. These kidney sections were also co-labeled with Cux1. In comparison to the 
Pkd1CD kidneys, which showed an increase in cell proliferation (Figure 3-5 C), cell proliferation 
was reduced in the Pkd1CD/Cux1ΔHD+/- kidneys. Nevertheless, there were proliferating cells 
Figure 3-4 Reduced Cux1 gene dosage correlated with the expression of p27 in the 
Pkd1CD/Cux1ΔHD+/- kidneys. A-B: Kidney sections from Pkd1CD (A) and 
Pkd1CD/Cux1ΔHD+/- (B) mice were labeled with Cux1 (green) and merged with DAPI (blue) 
staining. Pkd1CD kidneys showed the presence of nuclear Cux1 (arrows in A). 
Pkd1CD/Cux1ΔHD+/- kidneys showed both nuclear (arrowheads in B) and cytoplasmic (arrows 
in B) staining of Cux1. C-D: Kidney sections from Pkd1CD (C) and Pkd1CD/Cux1ΔHD+/- (D) 
mice were co-labeled with p27 (green) and cytokeratin (red). These images were merged 
together. Cytokeratin positive cysts in Pkd1CD kidneys did not show p27 expression (C). Some 
cytokeratin positive cysts and many normal tubules (arrows) showed p27 expression (D). A-D 
Scale bar= 50µm. E: Whole kidney lysates were prepared from P15 Pkd1CD and P23 
Pkd1CD/Cux1ΔHD+/- mice. A western blot analysis was done on these lysates with antibodies 
raised against p27 and β-tubulin (loading control). We saw an increase in the expression of p27 
in the Pkd1CD/Cux1ΔHD+/- kidneys compared to Pkd1CD kidneys. F: Relative intensity of p27 
bands compared to the loading control is shown. 
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lining Pkd1CD/Cux1ΔHD+/- renal cysts. Cux1 and PCNA co-localized in many cyst-lining cells, 
however, there were some cells which were positive for Cux1 but negative for PCNA (Figure 3-5 
D).  
Increase in the expression of p27 is associated with a decrease in cell proliferation in 
Pkd1CD/Cux1ΔHD+/- kidneys. 
Kidney sections from the Pkd1CD/Cux1ΔHD+/- mice were co-labeled with p27 and PCNA 
antibodies. Increased p27 expression was seen mainly in the cyst-lining cells of smaller cysts. 
Co-localization of p27 and PCNA was seen only in a subset of cyst-lining cells. Small cystic 
dilations were devoid of PCNA while they continued to express p27. At the same time, we also 
observed PCNA positive cells which were negative for p27 (Figure 3-5 E). 
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Discussion 
  ADPKD is a systemic disorder characterized primarily by renal cysts and several extra-
renal manifestations (2). At a molecular level, ADPKD shows increased cell proliferation and 
apoptosis of the cyst-lining epithelia, increased fluid secretion, extracellular matrix abnormalities 
and epithelial polarity defects (11). Several functions have been described for polycystins, 
mutations in which are responsible for ADPKD. Previous studies show that polycystins induce 
the expression of the CKI, p21, by inhibiting cdk2. This upregulation of p21 leads to cell cycle 
arrest at G0/G1 (48). However, in the case of ADPKD, where either of the polycystins are 
mutated, this cell cycle arrest may not occur which can lead to increased cell proliferation.  
There is debate about which molecular pathogenic event happens first in order to initiate 
cystogenesis. However, increased cell proliferation is a hallmark feature of PKD kidneys. 
Increased cell proliferation can be explained by the involvement of polycystins in the cell cycle 
Figure 3-5 Analysis of cell proliferation and apoptosis in Pkd1CD and Pkd1CD/Cux1ΔHD+/-
kidneys. A -B: TUNEL assay (green) was done on Pkd1CD (A) and Pkd1CD/Cux1ΔHD+/-  (B) 
kidney sections and the images were merged with DAPI (blue) staining. Increased apoptosis was 
seen in both Pkd1CD and Pkd1CD/Cux1ΔHD+/-   kidneys. Most of the cyst-lining epithelial cells 
(arrows in A and B) were positive for TUNEL staining. Some normal renal tubules in the 
Pkd1CD/Cux1ΔHD+/- kidneys were also TUNEL positive (arrowheads in B). C-D: Kidney 
sections from Pkd1CD and Pkd1CD/Cux1ΔHD+/- mice were co-labeled with Cux1 (green) and 
PCNA (red), a cell proliferation marker. Merged images are shown. Increased cell proliferation 
was seen in the Pkd1CD kidneys (C). A decrease in cell proliferation was seen in the 
Pkd1CD/Cux1ΔHD+/- kidneys as seen by PCNA staining (arrows in D). Some cyst-lining cells 
were positive for Cux1 but not for PCNA (arrowheads in D). A-D, scale bar= 100µm. E: Kidney 
sections from Pkd1CD/Cux1ΔHD+/- mice were stained with p27 (green) and PCNA (red). Many 
of the cyst-lining and normal epithelial cells were negative for PCNA staining. This pattern also 
correlated with an increase in the expression of p27 in these cells (arrows). Few cells which 
were positive for PCNA, did not show p27 labeling (*). Co-localization of p27 and PCNA were 
seen in a very few cells (arrowheads). E, scale bar=50µm.  
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and also by the dysregulated expression of many cell cycle related genes such as EGF, TGF, the 
mTOR pathway, (11) and also Cux1, on which we focused our research.  
We generated a double mutant mouse model by deleting Cux1 and Pkd1. The deletion of 
Pkd1 was specifically restricted to the renal collecting ducts. Analysis of newborn homozygous 
double mutant mice (Pkd1CD/Cux1ΔHD-/-) showed a complete absence or significantly fewer 
renal cysts in comparison to newborn Pkd1CD mice. Compared to their homozygous counterparts 
(Pkd1CD/Cux1ΔHD-/-), newborn heterozygous Pkd1CD/Cux1ΔHD+/- mice had more cysts, but 
fewer than Pkd1CD kidneys. These results demonstrate that even though there is a complete 
functional loss of Cux1 that reduces cell proliferation to an extent, cysts can still form.  
Heterozygous Pkd1CD/Cux1ΔHD+/- kidneys at P23 showed a significant reduction in 
cystogenesis. While cystic kidneys from the Pkd1CD mice were crowded with medium and large 
cysts, the Pkd1CD/Cux1ΔHD+/- kidneys showed primarily small cysts and preservation of normal 
renal parenchyma. The observation of more small cysts in the Pkd1CD/Cux1ΔHD+/- kidneys 
suggests that the cysts that formed were not progressing as fast as cysts in the Pkd1CD kidneys. A 
reduction in Cux1 gene dosage was unable to prevent cysts from forming, however, it slowed 
down the process of cystogenesis probably through a reduction in cell proliferation.  
Cell proliferation was reduced in the Pkd1CD/Cux1ΔHD+/- kidneys compared to the 
Pkd1CD kidneys. Many of the non-proliferative cells in the Pkd1CD/Cux1ΔHD+/- kidneys also 
showed increased expression of p27, a CKI transcriptionally repressed by Cux1. The increase in 
the expression of p27 was seen in many normal tubules as well as cysts and noticeably more in 
smaller cystic dilations. Western blot analysis of these kidneys also confirmed the increased 
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expression of p27. In comparison to the Pkd1CD kidneys, p27 was up-regulated in the 
Pkd1CD/Cux1ΔHD+/- kidneys.  
The analysis of apoptosis in the Pkd1CD/Cux1ΔHD+/- kidneys showed similar results as 
observed during late stage cystogenesis in the Pkd1CD mice. Most of the cyst-lining cells 
expressed Cux1 and were TUNEL positive. The TUNEL positive cyst-lining cells may be 
explained by the opposing signals that these cells receive: 1) a mutation in the Pkd1 gene which 
signals the cells to proliferate probably as a compensatory mechanism, 2) an increase in p27 
which gives them a signal to arrest at G0/G1. These contrasting signals may force the cyst-lining 
cells and the normal collecting duct epithelia which has a deletion in the Pkd1 gene to undergo 
apoptosis.  
Results from the Pkd1CD and Pkd1CD/Cux1ΔHD mouse models can be summarized as 
follows. In the Pkd1CD mouse model, there is an increase in the expression of Cux1 owing to the 
mutation of the Pkd1 gene in renal collecting ducts. This increase in Cux1 leads to an inhibition 
of p27, allowing them to progress through the cell cycle. This in turn leads to an increase in cell 
proliferation leading to severe PKD by P7. 
The Pkd1CD/Cux1ΔHD+/- mouse model has a targeted deletion in Cux1 together with a 
conditional deletion of the Pkd1 gene in collecting ducts. The Cux1ΔHD mutation renders the 
mutant Cux1 protein unable to enter the nucleus. A reduction in the dosage of functional Cux1 
results in the de-repression of p27 and hence an arrest of cells in the G0/G1 phase of the cell 
cycle. This leads to the decrease in cell proliferation observed in the Pkd1CD/Cux1ΔHD+/- 
kidneys. Owing to the innate Pkd1 mutation in the collecting ducts, cystogenesis occurs in these 
kidneys. However, the de-repression of p27 acts as a break, slowing down one of the important 
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pathogenic aspects in PKD, cell proliferation. Taken together, our results suggest that by 
decreasing cell proliferation, we can partially rescue PKD in an ADPKD mouse model. Rather 
than preventing cystogenesis altogether, this mechanism considerably slowed down the process 
of cyst development.  
Even though the reduction in Cux1 gene dosage slowed down the process of cystogenesis 
in Pkd1CD/Cux1ΔHD+/- mice, these mice exhibited an increase in flank size typical of PKD by 
P29, and died soon thereafter. Our previous results suggest a role for the nuclear isoform of 
cathepsin-L in ADPKD. Cathepsin-L cleaves the full length Cux1 to generate shorter isoforms of 
Cux1. A reduction in cathepsin-L and a concomitant accumulation of the full length Cux1 was 
observed in ADPKD patients, as well as in the Pkd1 null mouse model (87). We speculate that 
the reduction in cathepsin-L, and the resulting accumulation of the full length Cux1 from the 
normal Cux1 allele in the Pkd1CD/Cux1ΔHD+/- animals eventually leads to severe PKD.  
One of the mechanisms through which polycystins exert their regulatory role in cell cycle 
is by signaling through the JAK-STAT pathway. It has been shown that polycystin 1 binds to 
Jak2 and regulate STATs 1, 3 and 6 (50-51). Research in the obesity field shows that cathepsin-L 
is also regulated by STAT3 (128). These results suggest a role for polycystins in regulating Cux1 
through STAT3 and cathepsin-L. A detailed study evaluating the expression pattern and levels of 
cathepsin-L and STAT3 in Pkd1CD and Pkd1CD/Cux1ΔHD may give conclusive information in 
this regard.  
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Chapter Four 
Conclusions and future directions 
A potential role for the homeodomain protein Cux1 in PKD was established by the 
observations that it was ectopically expressed in several mouse models of PKD and also in 
ADPKD patients (87-88, 124). In order to determine whether ectopic expression of Cux1 induces 
cysts in mice, Ledford et al made a transgenic mouse model which overexpressed Cux1. The 
global overexpression of Cux1 in these mice led to multiorgan hyperplasia including kidney 
hyperplasia, however, they did not develop PKD (101). This suggested that the overexpression of 
Cux1 is not enough to induce cystogenesis.  
As a next step in elucidating the role of Cux1 in PKD, I set out to test the hypothesis that 
Cux1 is required for cystogenesis or cyst progression in ADPKD. Because Pkd1 null mice die 
embryonically (60), we first generated an ADPKD mouse model with the conditional 
inactivation of the Pkd1 gene in renal collecting ducts (Pkd1CD). The Pkd1CD mice were then 
used to generate a double mutant mouse model which had a homozygous deletion in the Pkd1 
gene together with a targeted deletion in the Cux1 gene (Pkd1CD/Cux1ΔHD).  
The Cux1ΔHD mouse model which I used in generating the Pkd1CD/Cux1ΔHD mice had 
a 4kb deletion in the Cux1 gene. This deletion in the Cux1 gene generates a mutant Cux1ΔHD 
protein which has a loss of its C-terminal domain encompassing the homeodomain, repression 
domain and more particularly a loss of its nuclear localization sequence (NLS). The loss of the 
NLS in the Cux1ΔHD mutant protein makes it functionally inactive since Cux1 is a transcription 
factor which functions in the nucleus. The Cux1ΔHD homozygous null mice do not show any 
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renal phenotype. However, they display stunted growth, have difficulty thriving, have increased 
susceptibility to bacterial infections and most of them die within a week after birth. The 
Cux1ΔHD heterozygous mice were indistinguishable from their wild type littermates and did not 
have any developmental abnormalities (122-123).  
First, we analyzed the Cux1ΔHD null mice carrying a collecting duct specific deletion in 
the Pkd1 gene (hereafter Pkd1CD/ Cux1ΔHD-/-). These mice had a complete loss of function of 
Cux1 since they had lost both the normal copies of Cux1. Analysis of newborn Pkd1CD/ 
Cux1ΔHD-/- mice showed either an absence of renal cysts or if cysts were present they were very 
few and smaller compared to the renal cysts in the Pkd1CD mice. This suggested that the loss of 
Cux1 has slowed down the cystogenesis process. However, the presence of renal cysts in these 
mice show that Cux1 is not required for cyst initiation.  
Because of the perinatal lethality of the Pkd1CD/ Cux1ΔHD-/- mice we focused our studies 
mainly on Cux1ΔHD heterozygous mice carrying a collecting duct specific deletion in the Pkd1 
gene (hereafter Pkd1CD/ Cux1ΔHD+/-). As the genotype implies, these mice have one normal 
copy of the Cux1 gene and the protein transcribed from this allele can enter the nucleus. The 
other Cux1 allele generates a mutant Cux1ΔHD protein which gets excluded from the nucleus 
because of the loss of its NLS, leaving it as a non-functional protein.  
Analysis of the newborn Pkd1CD/ Cux1ΔHD+/- kidneys showed the presence of renal 
cysts, however, they were smaller and fewer compared to the renal cysts in the Pkd1CD mice. 
This suggests that the reduced gene dosage of Cux1 in these mice slowed down the cystogenesis 
process. Further analysis of the Pkd1CD/ Cux1ΔHD+/- mice at postnatal day 23 (P23) showed that 
these mice had fewer renal cysts and a preservation of normal renal parenchyma compared to the 
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Pkd1CD kidneys which were crowded with cystic tissue even at P15. Consistent with the 
reduction of the gene dosage in Cux1, the Pkd1CD/ Cux1ΔHD+/- kidneys showed an ectopic 
expression of p27, which is a transcriptional repression target of Cux1. The ectopic expression of 
p27 in these kidneys led to a decrease in cell proliferation resulting in the slow progression of the 
disease.  
Even though ADPKD is considered an adult onset disease, cysts as big as 7mm are 
observed at birth in children with ADPKD. A recent study by Grantham et al measured the 
diameter, volume and growth rates of individual cysts in adult ADPKD patients by magnetic 
resonance imaging over a period of 3 years. This study showed that the growth rate of cysts in 
these adult patients was far less than the rate which is required to develop a cyst with a 7mm 
diameter at birth. This suggested that the in utero environment may be very conducive for 
cystogenesis and therefore many of the cysts that are detectable at birth may have gone through 
exuberant growth rates in utero (18). Therefore, treating ADPKD patients in the in utero period 
could be a promising approach in order to effectively halt the cystogenesis program. However, at 
present, it is impractical and perhaps unethical. Nevertheless, our results with the Pkd1CD/ 
Cux1ΔHD mice show the effectiveness of such treatments since these mice presented with fewer 
and smaller renal cysts at birth. We speculate that the loss or the reduction in Cux1 gene dosage 
and the resultant increase in p27 may have put a brake on the exuberant in utero cystogenesis 
process by decreasing cell proliferation.  
Another CKI, p21 is also a transcriptional repression target of Cux1 (118). We did not 
see any change in the expression of p21 in the Pkd1CD/ Cux1ΔHD+/- kidneys. One possible 
explanation is that the levels of p21 are normally downregulated very early on during kidney 
development. Therefore, p21 may have an effect in reducing cell proliferation in the 
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Pkd1CD/Cux1ΔHD+/- kidneys during early kidney development. We cannot exclude this 
possibility since we have not studied the Pkd1CD/Cux1ΔHD +/- kidneys embryonically. 
Nevertheless, p21 is a very appealing target in reducing cell proliferation in PKD since 
polycystins also up-regulate the levels of p21 thereby decreasing cell proliferation (48-49). 
However, abundant evidence suggests that p27 may play a more important role in decreasing cell 
proliferation than p21. For example, inactivation of p21 in mice showed no developmental 
defects suggesting that there may be other pathways which can compensate for the loss of p21 
(127). In contrast, inactivating p27 has a major impact as it results in hyperplasia and an increase 
in the size of many organs including kidneys showing the importance of p27 in decreasing cell 
proliferation (126).  
Additional evidence for the importance of p27 in decreasing cell proliferation in PKD 
comes from the study by Alcalay et al (87). They generated a double mutant mouse model by 
crossing a Cux1 mutant (Cux1ΔCR1) to the cpk mouse model of PKD. This resulted in an 
aggravation of cystic disease in the cpk mouse when both the copies of Cux1 were mutated. 
However, mice which were heterozygous for the Cux1ΔCR1 mutation and homozygous for the 
cpk mutation did not show a significant difference in the size of their kidneys compared to the 
cpk cystic kidneys. They noticed that there was an ectopic expression of p27 in these kidneys but 
not of p21. This also suggested that it was the ectopic expression of p27 and a resultant decrease 
in cell proliferation which protected these kidneys from an aggravation of PKD (87). My studies 
with the Pkd1CD/Cux1ΔHD+/- also point towards p27 as the important player in reducing cell 
proliferation and thereby partially rescuing PKD in these mice. Together, these results suggest a 
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paradigm shift in the field of PKD where we show the importance of p27 over p21 in rescuing 
PKD. 
Increased cell proliferation is an important factor in the progression of PKD. Therefore, 
translational approaches have been aimed at targeting this important pathogenic pathway. 
Treatment of a PKD mouse model with roscovitine, a small molecule CKI, showed promising 
results as these mice showed reduced kidney weight to body weight ratio and cysts volumes 
(155). Roscovitine is a potent inhibitor of cdk2-cyclin E which functions by targeting the G1-S 
check point in the cell cycle that is regulated on a molecular level by the CKIs p27 and p21. It 
also inhibits cdk7, cdk9 and cdk5. At a molecular level, roscovitine binds to the ATP-binding 
pocket of the Cdks. Specifically, roscovitine inhibits cdk2 thereby preventing phosphorylation of 
Rb and keeping E2F transcription factor in its inactive state (156). MDCK cells which form 
cystic structures in 3D collagen gels were treated with roscovitine. This also resulted in a 
decrease in cell proliferation in these cells. Increased cell proliferation in PKD also results from 
the activation of the B-Raf/MEK/ERK pathway. Oral administration of a MEK inhibitor in a 
PKD mouse model was able to reduce cystogenesis and kidney enlargement (157). Overall, these 
studies suggest the importance of targeting the cell cycle pathway in PKD. 
Results from the Pkd1CD/Cux1ΔHD mice suggest that Cux1 and p27 are promising cell 
cycle targets for the treatment in ADPKD. If transcription factors become suitable targets for 
treatment by siRNA knockdown strategies, Cux1 is an important transcription factor that could 
be targeted in PKD. Our results show that reducing the levels of Cux1 can lead to a considerable 
reduction in cell proliferation and a partial rescue of PKD.  
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Our results also show that the reduced gene dosage of Cux1 exerts its effect by the up-
regulation of p27. Therefore another strategy will be to use p27 agonists to treat PKD. One of the 
follow-up studies that we are currently pursuing is to test if forced expression of p27 can lead to 
a greater or even complete rescue of PKD in the Pkd1CD mice. In order to do these experiments, 
a conditional floxed p27 transgenic mouse model (CMV/p27) has to be generated. The 
conditional p27 transgenic mouse model can then be used to generate a double mutant mouse 
model by crossing CMV/p27 to the Pkd1CD/+mice. These double mutant mice will have a 
simultaneous inactivation of the Pkd1 gene and a forced direct expression of p27 in the 
collecting ducts of the kidneys. Unlike the Pkd1CD/Cux1ΔHD+/- mouse model which had an 
increase in the expression of p27 because of the reduced Cux1 gene dosage, the Pkd1CD/ 
CMV/p27 double mutant mouse model will have a direct increase in the expression of p27. We 
speculate that this forced expression of p27 despite the inactivation of Pkd1 may lead to a greater 
or even complete rescue of PKD in the Pkd1CD animals. However, one challenge is that the 
forced expression of p27 starting from E9.5 in the ureteric bud derivatives of the kidneys may 
also lead to developmental defects of the kidneys since cell proliferation will be greatly 
inhibited.   
Even though the reduced Cux1 gene dosage in the Pkd1CD/Cux1ΔHD+/- mice results in 
slowing down cystogenesis and disease progression, these mice eventually die of renal failure by 
around 4 weeks of age. A study by Alcalay et al showed that a nuclear form of cathepsin-L, a 
protease that processes the full length isoform of Cux1, is reduced in ADPKD cells compared to 
the normal human kidney cells. A reduction in cathepsin-L was also shown in the Pkd1 null mice 
compared to the age-matched wild type controls (87). A regulatory loop among polycystin-1, 
STAT3, cathepsin-L and Cux1 has emerged recently. The Polycysin-1 C-terminal tail has been 
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shown to interact with STAT3. STAT3 has been shown to regulate cathepsin-L (51, 128). This 
suggests that the dysregulation of PC1 in ADPKD may be directly linked to the increased 
expression of Cux1 that is observed in the disease. In this model, a mutation in polycystin-1 
would lead to a reduction in STAT3 which would result in reduced levels of cathepsin-L and 
increased accumulation of the full length Cux1 isoform, leading to the repression of p27 and 
deregulated cell cycle progression. 
We speculate that the reduction in nuclear cathepsin-L also occurs in the 
Pkd1CD/Cux1ΔHD+/- mice. This reduction in cathepsin-L in the Pkd1CD/Cux1ΔHD+/- kidneys will 
result in a reduced proteolytic processing and accumulation of full length isoform of Cux1.The 
full length isoform of Cux1 functions by transcriptionally repressing p21 and p27.  Therefore, the 
accumulation of full length Cux1 eventually leads to increased cell proliferation and disease 
progression in the Pkd1CD/Cux1ΔHD+/- mice. However, the reduction to one functional Cux1 
allele in the Pkd1CD/Cux1ΔHD+/- mice makes this process of Cux1 accumulation slower, thereby 
slowing down disease progression. Thus, cathepsin-L is another potential target for treatment of 
ADPKD. An increase in the expression of nuclear cathepsin-L may lead to an increased 
processing of Cux1, prevent its accumulation, eventually leading to a decrease in cell 
proliferation.  
The Pkd1CD mouse model that we generated had a collecting duct specific deletion of the 
Pkd1 gene. From this mouse model, we learned a developmental aspect of PKD. In particular, 
we chose to delete Pkd1 in renal collecting ducts and not in any other segments of the nephron 
for the following reason: 
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Microdissection studies on human kidneys have revealed that cysts in ADPKD can arise 
from all segments of the nephron including the collecting ducts (5). However, most of the cysts 
in ADPKD patients develop from collecting ducts (18). Collecting duct cysts are also more 
numerous and larger than the cysts derived from other tubular segments (138). It is not known 
why most of the cysts originate from collecting ducts. However, we can speculate some reasons 
by analyzing the expression pattern of polycystins and some other proteins that are only 
expressed in the collecting ducts.  
Expression studies on human fetal kidneys show that polycystin expression in both 
cortical and medullary collecting ducts remains until 40 weeks of gestation, while proximal 
tubules sustain the expression only until 28 weeks of gestation. This pattern of expression 
suggests that polycystins are required for a longer time and may be more important in the 
collecting ducts than in other renal tubules. Murine polycystin-1 also shows a strong pattern of 
expression in the ureteric bud derivatives such as in collecting ducts, papillary ducts and the 
renal pelvis during the later developmental stages and this expression pattern continued until 
around 3 weeks after birth (31, 39). Both the human and murine polycystin-1 showed a weak 
expression in the ureteric bud tips. This suggests that polycystins may not be required for the 
initial metanephric induction. Since polycystins show a stronger and spatially restricted 
expression pattern in collecting ducts, when one of the polycystins is mutated, collecting ducts 
may be more affected than other nephron segments. 
Another reason for the predominance of collecting duct cysts may have to do with the 
urine concentrating function of the collecting ducts.  Principal cells in the collecting ducts 
express the receptor (V2R) for antidiuretic hormone (ADH), also known as arginine vasopressin 
(AVP). An increase in plasma osmolality leads to the secretion of AVP which binds to its 
  112
receptors on the collecting ducts.  This leads to the activation of adenylyl cyclase 6 (AC6) which 
in turn converts ATP to form the second messenger cAMP. The end result of this signaling 
pathway is the insertion of AQP-2 channels on the apical membrane of the principal cells and 
water intake into the cell. This signaling pathway, which occurs primarily in the collecting duct 
cells can lead to an increase in cAMP. cAMP has been shown to have mitogenic effects on 
ADPKD cells in contrast to its anti-mitogenic effects on normal human kidney cells.  Therefore, 
the presence of V2R on principal cells and its involvement in a signaling pathway which leads to 
the production of cAMP may make collecting ducts more susceptible to cystogenesis (138). 
Inactivation of Pkd1 in the Pkd1CD mice was achieved by E9.5 even before metanephric 
induction occurred. However, we did not see any cystic dilations in the Pkd1CD mice when we 
analyzed them between E14.5 –E15.5. This was not surprising since the Pkd1 null mice (global 
knockout of Pkd1) also did not show any cystic dilations until E15.5. These results suggest that 
the inactivation of the Pkd1 gene does not affect the early metanephric induction events. 
While the inactivation of Pkd1 in the Pkd1CD mice was restricted to the collecting ducts, 
these mice developed severe cystic disease by P7. Moreover, by P15, the normal renal 
parenchyma was completely destroyed and no normal renal tubules were seen. How can we 
account for the loss of other nephron segments here? Even though the mutation is restricted to 
the collecting ducts, the cysts that arise from them expand by increased cell proliferation. The 
expansion of these cysts likely resulted in the compression of the adjacent normal renal 
parenchyma leading to the apoptosis of normal renal tubules. Consistent with this, we saw 
increased TUNEL labeling in these kidneys.  
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Two other collecting duct specific PKD mouse models have been generated by Raphael 
et al (158). They inactivated Pkd1 specifically in the principal cells (PC) of mouse collecting 
ducts by using an AQP-2 Cre transgenic mouse. The PC-Pkd1 knockout mice did not show any 
cysts at birth, however, these mice showed cystic dilations at 1 week of age. They had an average 
life span of 8.2 weeks.  
In a separate experiment, the same group also generated another Pkd1 knockout mouse 
model by conditionally inactivating Pkd1 in the intercalated cells (IC) of mouse collecting ducts 
by using a B1 Cre transgenic mouse. In contrast to the PC-Pkd1 knockout mice, the IC-Pkd1 
knockout mice showed a mild cystic phenotype. They showed very few cysts even at 8-9 weeks 
of age. They attributed the phenotypic differences between the PC and IC knockouts to the 
possibility of ICs lacking the expression of PC1. They also suggested that PC1 may not also be 
functionally important in the ICs.  
Comparing the PC-Pkd1 knockout mouse model to our Pkd1CD mouse model, the Pkd1CD 
mouse model had a more severe phenotype compared to the PC-Pkd1 mouse model. We 
observed microscopic cystic dilations at birth in the Pkd1CD mice while no cysts were present in 
the newborn PC-Pkd1 mouse model. This difference can be explained by the use of different Cre 
recombinases to inactivate Pkd1 in these different mouse models. We used the Hoxb7/Cre 
transgenic mouse model which inactivates Pkd1 in the mesonephric duct by E 9.5. In contrast, in 
the PC-Pkd1 mouse model, Raphael et al used an AQP-2 Cre which is not active until E18.5. We 
did not see any cystic dilations in the Pkd1CD mice until E 15.5. The Pkd1CD mice likely had an 
active cystogenesis process between E15.5 and birth which resulted in the presence of 
microscopic cysts in the newborn mice. This is in accordance with the observation that most of 
  114
the cysts that we see in children and young adults with ADPKD must have gone through a 
process of exuberant growth in the fetal environment (18). 
The Pkd1CD and the PC-Pkd1 mouse models, both had an inactivation of Pkd1 
embryonically. Yet, the Pkd1CD mice developed a more severe and rapid disease than the PC-
Pkd1 mice.  In the PC-Pkd1 mice, Pkd1 is inactivated at E18.5. The fact that AQP2-Cre is active 
in these cells suggests that these cells have differentiated at least partly if not completely and 
have the characteristics of a collecting duct cell. In contrast, the Pkd1CD mice suffered a Pkd1 
mutation at E9.5 when these progenitor collecting duct cells were still in the early stages of 
development. This difference of inactivating Pkd1 in the progenitor cells versus differentiated 
cells may have profound effects. Kidney development is characterized by the reciprocal 
induction events between the collecting duct progenitor cells and the cells in the metanephric 
mesenchyme. Therefore, the loss of polycystin-1 starting from E9.5 in the collecting duct 
progenitor cells in the Pkd1CD mice may have had an impact on further kidney development. It is 
possible that the loss of polycytsin-1 in these cells may have left them undifferentiated.  
Overall, my dissertation work shows that Cux1, a cell cycle regulatory gene is required 
for cyst progression in ADPKD emphasizing the importance of increased cell proliferation in the 
pathogenesis of ADPKD. Accordingly, Cux1, cathepsin-L, which is upstream of Cux1, and p27, 
the downstream target of Cux1, may be possible targets for pharmacological intervention in 
ADPKD. Our results also show that reducing the gene dosage of Cux1 and thereby reducing cell 
proliferation embryonically can slow down the cyst initiation process since we see only few and 
small cysts in the Pkd1CD/Cux1ΔHD mice. Our results also indicate that p27 is a major player in 
reducing cell proliferation in PKD. Finally, our results from the Pkd1CD mice show that 
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inactivating Pkd1 in the progenitor cells can have a profound effect in the progression of PKD 
compared to the inactivation of this gene in differentiated cells. 
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